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Abstract 
Author: Eimear Kennedy 
Thesis Title: Characterisation of resident multipotent vascular stem cell derived 
smooth muscle cells in culture 
The origin of the vascular Smooth Muscle Cell (SMC) involved with vascular 
remodelling is very controversial. The theory that SMCs can dedifferentiate is long 
standing. However, in more recent years this idea has been challenged with the 
emergence of resident progenitor stem cells in the vascular wall. Here, a population 
of primary Multipotent Vascular Stem Cells (MVSCs) were isolated using explant 
culture from the medial layer of rat aortic tissue. MVSCs were characterised for 
multipotency based on expression of neural crest markers Sox10, Sox17 and glia cell 
marker S100β. The cells were also characterised for their mesenchymal stem cell 
(MSC) like properties through their ability to differentiate into adipocytes and 
osteocytes and expression of markers CD44 and CD29. In maintenance media, the 
cells displayed a SMA+/CNN+/SM-MHCII- phenotype. After TGFβ1 and PDGF-BB 
stimulation the cells presented a SMA+/CNN+/SM-MHCII+ phenotype demonstrating 
their transition to SMCs. A10 and A7r5 cell lines are derived from the thoracic aorta 
of rat embryos. They are used widely as a model for non-differentiated neonatal and 
neointimal vascular SMCs. The discovery of resident MVSCs in the cell wall 
prompted the evaluation of these embryonic lines in relation to MVSC markers 
[Sox10, Sox17, S100β]. These cells expressed all three MVSC markers while 
concomitantly expressing SMA, CNN1 and SM-MHCII. Upon serum deprivation 
both cell lines had increased SMA and CNN1 expression. Both cell lines showed 
some potential to differentiate into adipocytes. Adult SMC lines from three different 
sources (bovine, rat and murine) were screened for MVSC markers and were found 
to express all three markers along with SMC markers SMA, CNN1 and SM-MHCII. 
However, these cell lines did not give rise to adipocytes or osteocytes after 
stimulation with induction media. These results indicate that a population of resident 
progenitors do exist in the vessel wall and may contribute to vascular remodelling 
after injury. The expression of MVSC markers in A10, A7r5 and various SMC lines 
indicates that these cells still retain some of their stem cell like properties and may 
not be terminally differentiated as previously described. NE4C neural stem cells 
were analysed for their SMC differentiation capabilities. The cells show some 
potential as a model for MVSC to SMC after TGFβ1 stimulation but further 
experiments are required to conclude these results. 
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Chapter 1: 
Introduction 
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1.0 General Overview 
The main objective of this study was to discover if resident progenitor stem cells 
exist in the vessel wall. Aortic explant cultures were prepared from freshly isolated 
rat aortic tissue. These cells were grown up and characterised for MVSC markers 
Sox10, Sox17, S100β. The cells were then analysed for multipotency capabilities 
following treatment of cells with induction media for osteocyte and adipocyte 
differentiation. MVSCs were treated with TGFβ1 to induce smooth muscle cell 
differentiation. Two commercial cell lines, A10 and A7r5, both embyronic rat 
smooth muscle cell lines, were evaluated for stem cell properties by investigating 
their MVSC marker expression and their potential to differentiate to adipocytes. 
Commercially available adult smooth muscle cell lines from three different animal 
sources were evaluated for the expression of MVSC markers and potential to 
differentiate to adipocytes and osteocytes. The cell lines were also analysed for MSC 
marker expression including CD29, CD44 and CD146. The immortalised 
neuroectodermal derived stem cell line, NE4C was evaluated as a model for MVSCs. 
NE4Cs were analysed as MVSCs and the other cell lines were for MVSC markers 
and their ability to differentiate to adipocytes and osteocytes. The cells were also 
stimulated with TGFβ1 to induce smooth muscle cell differentiation. 
 
1.1 Cardiovascular Disease 
1.1.1 The Vasculature 
The vascular system consists of a network of blood vessels, macro and 
microvascular systems. The larger arteries supplying blood around the body to target 
organs are arteries and veins. The capillaries (venules and arterioles) of the micro-
system serve to supply the blood within organs and to smaller areas of the body. The 
primary function of these structures is to transport blood around the body. It is a vital 
system ensuring that oxygen and other fundamental nutrients reach the organs where 
they are needed. Arteries pump oxygenated blood from the heart to target organs. 
Blood passes through organs via capillaries. The small size and diameter of a 
capillary wall allows for the diffusion of nutrients and oxygen within the organ. The 
deoxygenated blood containing waste material then passes into the veins which carry 
	  3	  
	  
the blood back to the lungs where it can be expelled. The cycle continues in the 
lungs, where the blood is oxygenated and brought back to the heart. 
 
1.1.2 Vessel Structure 
Arteries and veins are composed of three different layers which can be seen in 
Figure 1.0.  
The tunica intima/endothelium; this is the thinnest innermost layer which consists of 
a monolayer of endothelial cells and plays a fundamental role in vessel homeostasis 
(Gimbrone et al 2000). These cells are connected to a basal lamina which is an 
extracellular membrane layer consisting of collagen, proteoglycans and glycans. 
Properties of the endothelium are very important for blood flow. The cells naturally 
promote an anti-thrombotic/anti-inflammatory surface (Gimbrone et al 2000). The 
flat alignment of the cells prevents friction and reduces turbulence allowing blood to 
pass smoothly and be pumped further distances around the body. There is an internal 
elastic membrane which contains pore like structures permitting the passage of 
material through the vessel wall. In veins, small valves connected to the endothelium 
are in place to prevent backflow of blood (Bonow et al 2011). 
The tunica media; this is the middle layer of the vessel and has elastic 
properties. It is composed of vascular smooth muscle cells, pericytes, elastin and 
proteoglycans. The cells and proteins are arranged in a fibrous manner contributing 
to the tough structure of the medial layer. The cell primarily attributed to the tunica 
media is the vascular smooth muscle cell, which is not terminally differentiated and 
thought to be capable of undergoing “phenotypic modulation”. 
The tunica adventitia; this is separated from the tunica media by a thin layer 
of elastin. It is the outer layer and consists of connective tissue and fibroblasts. It 
contains collagenous tissue and some elastic fibres. This layer is less rigid than its 
neighbouring medial layer. The radius of this vessel wall will vary between arties 
and veins, being slightly thicker in veins (Bonow et al 2011). 
 Recent evidence has suggested the existence of resident stem cell progenitors 
within the vessel wall (Tang et al 2012, Klein et al 2011, Hu et al 2002). The three 
layers of the vessel wall are thought to be home to some populations of stem cells, 
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varying in stemness at each layer, for example progenitor adventitial cells display 
Sca-1 and this marker is lost in the medial progenitor cells isolated by Tang et al 
2012. It is very difficult to pinpoint an exact phenotype or cell marker that can 
describe/identify a typical stem cell. Nevertheless, the vessel wall is very dynamic by 
nature and as a result different types of stem cells may exist to assist in the 
regeneration and remodelling following injury Tang et al 2012, Gomez and Owens 
2012, Xu et al 2010). These researchers, along with others have shown that stem cell 
populations exist within the two different layers but different conclusions relating to 
the phenotypic markers have been reached. 
Many different populations of stem cell have been identified displaying different 
markers of stemness (Naito et al. 2012, Wang et al. 2012a, Sainz et al. 2006).  
Research has shown that the adventitia is one major source of progenitor cells that 
contribute to vessel structure and to disease (Majesky et al. 2012), (Klein et al. 
2011), (Tigges & Stallcup 2013)). The endothelium also harbours stem cells. The 
role of endothelial progenitor stem cells and their contribution to pulmonary 
hypertension has recently been proposed (Doerschuk 2005). The increase of SMA 
found in lesions and other forms of pulmonary hypertension had been attributed to 
an increase in SMC number (Arciniegas et al. 2007). More recent research suggests 
that endothelial cells undergo a transition to SMA expressing mesenchymal stem 
cells and contribute to disease (Arciniegas et al. 2007). It has also been suggested 
that this endothelial to mesenchymal transition [EMT] can cause an increased 
production of extra cellular matrix and lead to the development and progression of 
pathological fibrosis (Piera-Velazquez et al. 2011). This transition is also thought to 
be induced in part by the TGFβ1 pathway  (Chen et al. 2012). 
 The most recent studies have indicated that populations of stem cells exists 
within the tunica media layer (Tang et al 2012, Sainz et al 2006, Tintut et al 2003, 
Hu et al 2002) The cells isolated have been shown to harbour multipotent potential 
similar to that of mesenchymal stem cells (Tintut et al 2003).  
Tang et al 2012 have isolated a population of progenitor cells displaying 
phenotypic markers associated with stem cells, Sox10, Sox17 and S100β. They show 
that these cells can differentiate into SMCs upon injury and contribute to intimal 
thickening of the artery and may be involved with disease. It is suggested that these 
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multipotent progenitor cells are the source of vascular disease ie restenosis and that 
the “de-differentiated” SMC is not involved in the process. 
	  
	  
Figure 1.0 Representative image of the layers of arteries and veins in 
cardiovascular system. Image adapted from Shier et al. 1996. 
	  
1.1.3 Vascular Disease 
Cardiovascular Disease (CVD) is a leading cause of death in the United States, with 
recent reports of one CVD related death in every 40 seconds (American Heart 
Association, 2013 update). In Europe CVD is responsible for 47% of deaths and 
40% of deaths within the EU (European Society of Cardiology 2012). Although 
CVD mortality rates have declined since the 1970’s in Ireland, statistics still show 
that CVD is the greatest cause of death, accounting for 31.8% of deaths in the first 
quarter of 2012 (CSO). 13% of premature deaths (under the age of 65) are from 
cardiovascular disease (Irish Heart Foundation). Different forms of cardiovascular 
disease exist. 
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1.1.4 Cardiovascular Disease 
As previously described, the function of the vascular system is to supply blood, 
oxygen and nutrients to the body’s vital organs. A lack of nutrients and oxygen to 
any organ can cause severe damage to the restricted organ and will have counter 
effects on connected organs. Some examples include: aneurysm, stroke, 
hypertension, arteriosclerosis and atherosclerosis. The primary cause of vascular 
disease is as a result of the blockage of vessels. This can happen in different ways 
such as a blood clot (thrombus), plaque formation or inward vessel remodelling 
(arteriosclerosis). A lot of vascular disease stems from arteriosclersosis (and 
atherosclerosis) whereby the vessel becomes obstructed and blood flow is restricted. 
The cells that are responsible for this obstruction has generated much debate and 
controversy in the context of the purported contributory role of resident vascular 
stem cells (Tang et al 2012, Nguyen et al. 2013). 
 
1.1.5 Etiology of vascular disease 
There are many factors associated with CVD (Jiang et al 2000). In more recent years 
there has been a lot of research into CVD and facts continually emerge. There has 
been a subsequent increase in media coverage to educate the general population 
about the causes of CVD disease. Most of the risks are interlinked and one can affect 
another. The main causes are obesity and smoking with counter side effects 
including activity level, stress, drinking habits, diet and high cholesterol. In the 
United States, the alarm was first raised in 1994 linking obesity to heart disease. The 
National Centre for Health Statistics reported that between 1988-1994 and 1999-
2000 that the prevalence of overweight adults increased from 55.9% to 64.5% and an 
increase in obesity from 22.9% to 30.5% (Flegal et al. 2010). Obesity is an 
independent factor of CVD (Poirier et al. 2006), and as a result a lot of publicity 
focuses on this. Another factor associated with CVD is smoking, early studies have 
shown that the rate of CVD has been shown to triple in those who smoke 20 
cigarettes a day (Doyle et al. 1964). Even passive smoking has shown to increase CV 
risk by 1.25% (He at al 1999). Genome Wide Association Studies have been 
undertaken to identify the genes linked to cardiovascular disease. Interestingly, the 
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TCTN1 gene has been linked to CVD in these studies. This gene has a role in 
hedgehog signalling during embryonic development (Erbilgin et al 2013). 
 
1.2 Arteriosclerosis 
Arteriosclerosis is a form of cardiovascular disease. It is defined by a symmetrical 
thickening of the vessel wall. It is primarily attributed to hypertension and elevated 
blood pressure. Hardening of the muscular tissue in vessel wall occurs and this 
results in a loss of elasticity and rigidity of the vessel wall (Fishbein and Fishbein 
2009). The process can occur over a long period of time without diagnosis. The 
disease becomes a problem when it restricts blood to organs, especially where the 
coronary artery is concerned and a lack of blood flow to the heart results. The 
disease can progress onto atherosclerosis (a sub form of arteriosclerosis), which can 
be a result of many factors such as fat build up, cholesterol and plaques formations 
(Fishbein and Fishbein 2009). 
 
 
Figure 1.1 Arterioslcerosis. Symmetrical thickening of the tunica media layer 
occurs. 
	  
1.3 Atherosclerosis 
Atherosclerosis is initiated by EC dysfunction (Ross et al. 1977), Quinn, et al. 1987). 
It is a form of asymmetrical vascular disease. NO depletion can occur and cause the 
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endothelial “activation” which leads to an inflammatory response activation 
initiating thrombosis (Cunningham & Gotlieb 2005a). Plaque builds up in regions of 
the vascular system causing the narrowing of the lumen of vessels. It can be 
distinguished by interactions between “a fibrous cap of smooth muscle and 
extracellular matrix that encloses a lipid rich core”. In the literature the plaque is 
described as being composed of lipids, cholesterol, Ca2+, SMCs which have migrated 
and other molecules located in the blood. More recently it is believed that these cells 
found in the plaque may be newly differentiated SMCs rather than proliferating or 
“de-differentiated” SMCs.  
There are different stages of atherosclerosis (Figure 1.2), some of which are 
completely silent until the build-up becomes too much pressure for the vessel to 
handle. It initially begins when the surface of the endothelium becomes activated. 
Circulating leukocytes adhere to the endothelium and migrate into the intima. 
Monocytes mature into macrophages (Kume et al. 1992), and uptake lipids which 
results in the formation of foam cells (Figure 1.2b). After this stage, the lesion can 
progress and SMCs/progenitor cells migrate/proliferate from the tunica media into 
the intimal layer with encouragement from the macrophages. The presence of these 
cells increases the amount of extracellular matrix molecules gathered in the lesion, 
including collagen, elastin and proteoglycans. SMCs and macrophages frequently die 
within the lesion but the lipids derived from these cells can continue to accumulate in 
the region of the plaque, creating a lipid core (Figure 1.2c). The ultimate stage of 
atherosclerosis is thrombosis (Libby et al. 2011). This is initiated when rupture or 
erosion of the lesion occurs. It is induced by changes in the anticoagulant state of the 
endothelium, overlying the plaque. The coagulation process is activated and tissue 
factor located in the inner core of the lesion is released due to the rupture. There is a 
decrease of antithrombotic properties on the endothelium (Landmesser et al. 2004), 
which increases pro thrombotic properties of the vascular wall, promotes coagulation 
and initiates thrombus formation (Laszik et al. 2001). The accumulation of blood 
around the plaque increases the clot diameter, and as a result of this blood flow is 
restricted (Figure 1.2d). Other environmental factors including hemodynamic factors 
such as cyclic strain and shear stress are also thought to contribute to atherosclerotic 
lesions (Jiang et al. 2000),  (Cunningham & Gotlieb 2005b). 
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Figure 1.2 The onset and development of atherosclerosis, adapted from Libby et al. 
2011.  
 
1.4 Current therapies for cardiovascular disease 
Basic treatment for cardiovascular disease can include techniques as simple as diet 
change and exercise. This type of treatment would be used for patients that are at the 
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very early stages and also as a prevention mechanism for at risk patients. More 
serious treatments include medicines and then after this surgery could be necessary. 
Medicines are prescribed to reduce strain on the heart and to relieve symptoms (Ara 
2004). There are different types of medicines available. Drugs called statins are used 
as cholesterol lowering drugs, antiplatelet treatment and anti-clotting/coagulant 
treatment uses Clopidogrel and Warfarin and medication known as Pentoxifylline 
(Trental) can be prescribed to increase blood supply to the extremities. Futher to this 
is, surgical treatment is needed the procedures that are carried out mainly include by-
pass surgery and stenting. By-pass surgery is a process whereby a vein or artery from 
another part of the body is removed and used to by-pass blockages in the heart. 
Stenting is the main application of this work and is discussed further below. 
 
1.5 Treatment of CVD using Stents 
If CVD has been identified in a patient there are certain treatments which can be 
undertaken. For the purpose of this project stented arteries/veins will be discussed. A 
treatment currently used is Angioplasty and Percutaneous Transluminal Coronary 
Angioplasty (PTCA) whereby a stent is introduced into the vessel. This process 
assists in shrinking the atherosclerotic plaque and widens the artery reducing the 
obstruction of blood flow (Figure 1.3). 
 
 
Figure 1.3 Stented Artery restores blood flow 
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A stent is a small metal mesh tube that serves to support the mechanical 
structure of the vessel in which it is placed. Stents are usually about 18mm in size 
and 3-3.5mm in diameter. The first stent to be used to treat a human patient was in 
1986 by Peul and Sigwart. Stents are inserted into the target vessel by a surgeon 
using an angioplasty balloon method. Although stents have been shown to reduce the 
rate of angiographic and clinical restenosis when compared with the  PTCA 
procedure, failure rates as high as 70% have been reported in plain stents (Bare 
Metal Stents (BMS)) (Haery et al. 2004). BMS were originally used, but 
developments have led to the discovery of Drug Eluting Stents (DES) which have 
proven to be superior and have reduced failure rates. The two main types of stent 
which currently used are stents coated with either Sirolimus or Paclitaxel drugs. 
Patients may receive Clopidogrel treatment at the same time (antiplatelet drug). 
Many trials have been undertaken to determine which stent is more appropriate in 
the RAVEL and SIRIUS trials. The cost of a stent is usually around $2500-2700 
(Bhatia et al. 2004). 
 
1.6 In-stent restenosis 
Ultimately, in-stent restenosis is when the stent stops doing its job. Stent failure is 
due to the re-occlusion (restenosis) of the vessel in the area where the stent has been 
implanted, whereby the gradual re-narrowing of the vessel can be observed 
(Nikolsky et al 2003). When stents are placed in vessels the metal can cut into the 
endothelial layer disrupting it and exposing the medial layer. Inflammatory cascades 
leading to an immune response is initiated similar to any other wound healing 
process that occurs in the body (Nikolsky et al 2003). This activates macrophages 
and platelets, signalling them to home in on the site of injury. 
These cells then signal proliferation of vascular smooth muscle and 
inflammatory cells. Cytokines and growth factors, recruited by monocytes, both 
accumulate at the site of injury at the endothelium. The presence of these factors 
causes vascular smooth muscle cell infiltration to the intimal layer (Marx et al. 
2011). In this context, it is proposed that the cytokines involved are directly involved 
with ‘SMC proliferation’ and that they prompt either the growth of de-differented 
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SMCs and/or the differentiation of resident progenitors to SMCs before they migrate 
to the site of the stent in the intimal layer and contribute to in stent restenosis (Nikol 
et al 1992). 
The mechanism by which restenosis occurs may be different from those that 
produce the primary atherosclerosis. Primary atherosclerosis plaque is usually 
hypocellular with collagen and lipid components, whereas secondary atherosclerosis 
is usually hypercellular containing extra cellular matrix (ECM). Smad is upregulated 
in injured arteries, this increase in Smad is associated with an increase in SMC 
proliferation and is found exclusively in restenoic lesions (pro SMCs) (Edlin et al. 
2009). Smad proteins are transducers of TGFβ. They are intracellular proteins that 
receive the extracellular signals from TGFBβ and act via the nucleus to influence 
gene transcription (Ikedo et al 2003).  
Once in-stent restenosis has occurred the chances of it re-occuring are very 
likely with rates from 30-70% (Haery et al. 2004). A gradual re-narrowing of the 
stent occurs between 3 and 12 months after stent placement. This phenomenon led to 
the development of DES which have proven more successful in delaying the process. 
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Figure 1.4 Developmental origin of the smooth muscle cell (adapted from Life Map 
Sciences, 2012) 
 
1.7 Smooth Muscle Cell Origin 
The recent developments suggesting that resident progenitor cells derived SMCs 
contribute to vascular remodelling has brought about great interest regarding smooth 
muscle cell development and origin. If the mechanism(s) responsible for stem cell 
derived SMC differentiation are elucidated, the development of specific therapeutics 
that can directly target these populations will follow. Targeting specific cell 
populations is very important in disease to minimise the side effects of a given drug. 
The origin of the smooth muscle cell is diverse and the embryological origins can 
differ. Vascular SMCs arise from approximately five different sources during 
embryogenesis (see Figure 1.4 for example). These include; neural crest, 
proepicardium, serosal mesothelium, secondary heart field and somites (Xie et al. 
2011a). This means that the origin of SMCs can vary depending on blood vessel and 
even within certain vessels there exists a difference in SMC origin for example, the 
aorta (Seidelmann et al. 2014), whereby there is a mixed population, the neural crest 
cells of the ectoderm give rise to the SMCs of the aortic arch and the mesoderm 
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gives rise to the ascending aorta. Similarly, the carotid is of neuroectoderm origin 
but the coronary artery is of epicardial origin. 
 
1.8 Smooth Muscle Cells in Culture 
The first reports identifying vascular smooth muscle cells in culture were by 
Champy, who described the cells as elongated cells with fibrillae and noted the loss 
of these characteristics after many passages (Lewis & Lewis 1914) who described 
the mitochondrial staining in smooth muscle cells and by Laquer who noted that 
contractility was present in explant SMCs. It is well accepted that SMC phenotype 
can be modulated in culture. This involves a process whereby the expression of 
certain markers can be difficult to identify and sometimes the expression of SMC 
differentiation markers can be lost in culture. SMCs respond differently to serum and 
this can affect their growth pattern, for example when SMCs are serum deprived 
there is a significant increase in SMC differentiation markers (Metz et al. 2012).  
 
1.9 Phenotypic Modulation/Switching 
This idea of “phenotypic modulation” of SMCs has been used to explain the 
proliferation and de-differentiation of SMCs both in culture and playing a role in 
vascular remodelling in vivo The theory that SMCs are not fully differentiated and 
can undergo phenotypic modulation/switching is widely accepted. In a review from 
(Gomez & Owens 2012) this concept is discussed. The author makes an important 
point that although this theory is accepted there have not been in depth studies into 
defining how SMCs acquire the alternative phenotype and contribute to vascular 
remodelling. Lineage tracing studies are very important for identifying the exact 
cells involved in vascular remodelling and much research to date lacks this system. 
This means that is difficult to define the origin of the SMCs involved in injury. More 
recently Tang et al 2012 have used a lineage tracing method to show that MVSCs are 
resident in vascular tissue and can be found in the lesion tissue after vascular injury. 
A previous study undertaken by (Rong et al. 2003) demonstrated how 
macrophage markers may be increased in SMCs in the lesion – meaning that some of 
the macrophage positive markers found may be of SMC origin, indicating that SMCs 
have great scope for modulation during vascular remodelling (Gomez & Owens 
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2012). In another study, (Bentzon et al. 2006) found that some of the macrophages 
associated with the lesion are not of bone marrow origin. There is a lot of different 
research suggesting different sources of the SMCs, yet there is a lack of knowledge 
about the exact origin of SMCs involved in lesions. 
 
1.10 Contractile versus Synthetic SMCS  
The dedifferentiation theory has led to the concept that two different smooth muscle 
cell types exist: contractile and synthetic. Contractile SMCs are recognised as being 
“mature” SMCs. Typically, they are elongated and spindle shaped cells. They 
produce extra cellular matrix proteins such as elastin and they display the three 
markers associated with early (SMA), middle (CNN1) and late (SM-MHCII) stage 
SMCs. Their proliferation and migration rates are much lower as the cells are in a 
state of quiescence in the vessel wall. They support the vessel wall due to their 
contractility and contribute to structural hemodynamics regarding cyclic strain and 
shear stress (Cunningham and Gotlieb 2005). In comparison SMCs with a synthetic 
phenotype are shorter and less elongated, they have a “cobblestone” morphology. 
There are more organelles present in synthetic SMCs as they play a role in protein 
synthesis and vessel development. Contractile SMCs have contractile filaments in 
place of these organelles. Synthetic SMCs show higher growth and migratory rates 
along with greater proliferation activity. Contractile cells in comparison remain in a 
more “dormant” state (Wanjare et al. 2013; Rensen et al. 2007). 
It is these “activated” synthetic cells which are thought to be the cells which 
have migrated from the tunica media to the intimal layer in in-stent restenosis. The 
source of the SMCs was previously attributed to the dedifferentiation of a SMC 
population from the vessel wall whereby a resident contractile SMC becomes 
activated under certain environmental conditions and dedifferentiates to a 
synthetic/proliferative phenotype (Rensen et al. 2007). The dispute continues as to 
whether or not these cells are directly involved or if a population of resident stem 
cells could be the cause. Currently, there is a lot of conflicting information regarding 
the origin of these SMCs within the lesion. It has only more recently become 
accepted that the accumulation of these cells may be sourced from progenitor 
resident stem cells (mainly Mesenchymal Stem Cells) present in the vessel wall 
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(Tang et al. 2012b; Klein et al. 2011; Naito et al. 2012). A precise location of the 
stem cell niche has yet to be identified, unlike in other organs such as the intestine 
whereby the exact mechanisms are understood (Barker et al. 2008).  
 
1.11 Smooth Muscle Myosin Heavy Chain II expression in Culture 
The lack of expression of SM-MHCII in culture is associated with 
proliferating/synthetic SMCs (Fukuda & Aikawa 2010a; Aikawa et al. 1997). Up 
until recently it was widely accepted that SM-MHC negative (SM-MHC-) cells in 
culture were of a synthetic and/or proliferative phenotype (Orlandi et al. 1994; 
Nakajima et al. 1993). It has been thought that as SMCs are grown in culture that 
they lose their SM-MHCII expression, with this loss being attributed to the transition 
of contractile SMCs to a synthetic phenotype.  
 
1.12 Evidence of Smooth muscle progenitor cells 
 
1.12.1 Resident Vascular Stem Cells 
From as early as 1996 canine studies researchers have proposed the idea that resident 
progenitor cells exists in the vasculature (Holifield et al. 1996). Hu et al 2004 
suggests a role for MSCs in vascular disease, whereby they differentiate into SMCs 
and contribute to an atherosclerotic plaque. Originally it was thought that the cells 
involved accumulated as a result of PDGF being released by injured ECs and 
platelets (Ross et al. 1977). In transplant studies, Hu et al. have shown that about 
60% of the SMCs in atherosclerotic lesions have been derived from the donor vessel 
and the remaining 40% has been attributed to the recipients, which could be from 
circulating progenitors in the blood. These researchers showed that progenitor cells 
were present in the adventitia and could differentiate into SMCs in vitro and in vivo 
using ApoE deficient mice (Hu et al 2002). 
In another case, Tang et al. 2012 have identified a population of cells within 
the tunica media that express unique markers associated with stem cells/neural crest 
cells, Sox10, Sox17 and astrocyte marker S100β. They show that an isolated pool of 
Mulitpotent Vascular Stem Cells (MVSCs) can differentiate into SMCs in vivo and 
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in vitro, using SM-MHC and a GFP (Green Fluorescent Protein) lineage tracing 
system. Their research shows that in response to vascular injury these specific 
MVSCs become proliferative and differentiate into SMCs and it is these newly 
differentiated SMCs which contribute to vascular remodelling (neointimal 
hyperplasia).   
In a similar study from 2011, Klein et al published a paper whereby vascular 
wall-resident Multipotent stem cells give rise to pericytes and SMCs which 
contribute to new vessel maturation. The cells identified by this team are CD44+ and 
are isolated from the adventitia. It is also agreed here that vessel formation (SMC 
differentiation) both physiological and pathological begins in the vasculogenic 
zone/niche.  
A recent study (Tsai et al. 2012) has demonstrated that the cells repopulating 
a de-cellularized graft arise from a progenitor cell type, with markers for ECs, SMCs 
and stem cells found within a newly formed neointima. Repopulated cells were 
confirmed not to be bone marrow derived by use of a chimeric mouse model 
whereby a SM22-LacZ bone marrow was transplanted into a wild type mouse, then 
use of βgal staining.  
Overall, there is a lack of knowledge regarding the exact phenotype of 
resident progenitor stem cells as no “standard” progenitor cell has been identified. 
To some extent this topic is under-developed, which is acceptable because the idea 
that of resident progenitors exists is relatively new and not widely accepted. 
However, in order for model to be conducted that will have an impact on human 
health a considerable amount of research is required in this area. 
 
1.12.2 Circulating progenitors and Bone Marrow derived stem cells 
Circulating stem cells and those derived from the bone marrow have been reported to 
play a role in the re-endothelialisation of vessels after injury and to contribute to 
neointimal lesions using a GFP murine model (Tanaka et al. 2008). Notch signalling 
has also been shown to regulate the differentiation of bone marrow derived cells into 
cells with smooth muscle cell characteristics (increased expression of SMA) during 
arterial lesion formations (Doi et al. 2009). Other studies from (Saiura et al. 2001) 
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have recognised that these circulating stem cells can contribute to atherosclerosis. 
Interestingly, (Sata et al. 2002) found that hematopoetic stem cells could 
differentiate into vascular cells that then contribute to atherosclerosis. However, 
some researchers have dismissed this idea and  
It is possible that a combination of circulating progenitor cells and bone 
marrow derived cells are involved with contribution to vascular remodelling, 
depending on the degree of damage or measurement of strain acting on the vessel 
wall, with the possibility that progenitors may only be recruited from the bone 
marrow if the injury is of a high degree to help with SMC differentiation. 
 
 
 
 
 
 
 
 
Figure 1.5 The location of progenitor cells associated with the vasculature. 
 
1.12.3 Mesenchymal Stem Cells 
Mesenhcymal stem cells were originally identified in the bone marrow and as 
research progressed, other tissues were revealed as a source for mesenchymal stem 
cells, one of which includes vascular tissue (Crisan et al. 2008). MSCs are mainly 
adult stem cells that have the capacity for self-renewal and differentiation. They can 
contribute to mesoderm and non-mesoderm lineages (Williams & Hare 2011). Due 
to their diversity, MSCs could possibly serve as a good target for tissue regeneration. 
MSCs have been transplanted into animal models of myocardial infarction and have 
shown to differentiate into cardiomyocytes and vascular cells (Shake et al. 2002); 
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(Toma et al. 2002). MSCs are defined by their capability to differentiate into 
adipocytes, chondrocytes and osteocytes  (Figure 1.6) (Dominici et al. 2006). It is 
difficult to completely define the profile of an MSC as the range of markers 
associated with the cells is quite diverse and there are many cross overs with other 
cell types. Cluster of Differentiation (CD) markers are present on the surface of 
MSCs, and these markers are mainly used to identify the cells. However, many CDs 
have been linked to MSCs. The most common surface markers used to define an 
MSC in the literature include; CD146, CD44, CD29, CD105 and CD90 along with 
others (Lv et al. 2014). Other MSCs with a more immature phenotype have also been 
identified and express Sox2 and Oct-4, markers associated with embryonic stem cells 
(Iwata et al. 2010); (Kuroda et al. 2010). Differences in murine and human MSCs 
have been identified by (Peister et al. 2004). This limits the amount of work that can 
be done on animal models. More work is needed to identify markers specific to 
MSCs to give the cells more scope for use in regenerative medicine. 
In relation to cardiovascular disease, MSC progenitors have been identified 
in the artery wall (Abedin et al. 2004), and have been shown to participate in the 
restenoic response (Tigges & Stallcup 2013). Interestingly, in 1967 Robert Wissler 
described smooth muscle cells as “multifunctional mesenchymal stem cells”, 
foreshadowing the more recent findings for multipotent mesenchymal stem cells in 
the artery wall. Atherosclerotic lesions have been shown to contain mature bone 
tissue (Seemayer et al. 1973), and also cartilage (Christian & Fitzpatrick 1999). 
Evidence of MSC derived cells in atherosclerotic lesions indicates the presence of 
MSC progenitor cells in the artery. It also presents the argument that MSC 
differentiation is involved in vascular disease. MSCs have been shown to 
differentiate to SMCs via Notch and TGFβ signalling (Kurpinski et al. 2010). 
(Bajpai et al. 2012a), have shown that human iPSC derived MSCs can differentiate 
into SMCs by use of TGFβ. Research into the types of MSC involved in vascular 
remodelling has changed in recent years, with a bigger focus on multipotent 
progenitor stem cells resident in the vessel walls (Wang et al. 2012b). 
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Figure 1.6 Mesenchymal trilineage transition; adipocyte, osteocyte and 
chondrocyte. (Chondrocyte image, John Hopkins Medicine). 
 
1.13 Smooth Muscle Cells 
As described previously, vascular smooth muscle cells are found in the medial layer 
of arteries and veins and control tone and contractility in the vessel. Common 
markers associated with smooth muscle cells include smooth muscle alpha actin 
(SMA), Calponin 1 (CNN1), smooth muscle heavy chain myosin II (SM-
MHCII/Sm-2/Myh11), SM22 and Smoothelin. SMA is often used in research to 
identify SMCs as an early stage marker for SMC differentiation. However, this 
marker is an early non-specific SMC marker, with SMA being found in other cell 
lines such as endothelial cells (Azuma et al 2009). Moreover, sub endothelial cells in 
atherosclerotic lesion have been found to express both SMA and macrophage marker 
CD68 which can make it difficult to identify the cells involved in lesions with the 
marker cross over (Andreeva et al. 1997). More recently, monocytes have been 
shown to express SMA (Ludin et al. 2012).CNN1 is associated with being a middle 
stage marker, SM-MHCII is recognised as being a late stage marker for contractile 
SMC differentiation (Rensen et al. 2007).  
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1.14 Models for Vascular Cells in Culture 
1.14.1 A10 and A7r5 Embryonic Stem Cell lines 
A10 and A7r5 cell lines are embryonic vascular smooth muscle cell lines. They are 
rat cell lines which have been derived from the thoracic aorta of 14-17 day old 
embryonic BD1X rats. These cell lines have been used by research groups as models 
for vascular smooth muscle cells, representing a non-differentiated, neonatal and 
neointimal cell population (Rao et al. 1997). The cells have also been described as 
non-differentiated SMCS (Rao et al. 1997). Due to this and their embryonic origin, it 
was of great interest to re-examine these cell lines with regard to their stem cell 
marker expression in culture. 
 
1.14.2 NE-4C Neural Crest Stem Cells as a Model for SMCs tranition form 
Neural progenitors 
Neural crest stem cells are a type of stem cell that give rise to many neural crest 
derivatives (Teng & Labosky 2006). These include neurons, glial cells in the 
peripheral nervous system and skin melanocytes, these types are deemed “neural 
deriviatives”. However the neural crest can also give rise to non-neural cell types 
including mesenchymal associated cell types such as chondrocytes and adipocytes 
(Le Douarin et al. 2008). One of the purposes of this study was to investigate if an 
immortalised neural crest stem cell line like NE4C could be used as a model for 
neuroectodermal differentiation to SMC, typical of MVSCs. Therefore the potential 
of NE4C differentiation to SMC was investigated.  
 
1.15     Neural Crest Stem Cell fate 
The fate of neural crest stem cells (NCSC) like many other progenitor cell types, 
depends on how they are cultured and the components of their growth and 
maintenance media (Le Dourain et al 2008). When NCSCs are cultured in FBS they 
can easily differentiate due to the undefined nature of FBS. Rat NCSC have been 
shown capable of differentiation to a variety of neural crest lineages by use of 
BMP6, BMP7, GDF5 and GDF6. For examples BMP7 in particular was shown to 
induce smooth muscle and peripheral glial differentiation (Gajavelli et al. 2004). 
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NCSCs have also differentiated to astrocytes using retenoic acid in the presence of 
LIF (Asano et al. 2009). Specifically speaking, NE4C cells have been shown to 
produce neurons upon co-culture with with astroglia cells. Interestingly, it was also 
suggested that the co-culture of astroglia cells with embryonic stem cells did not 
result in neuronal differentiation (Kornyei et al 2005). In additon, induction with 
media containing Neuregulin I, glial differentiation was observed (Adlkofer & Lai 
2000). 
 
1.16 Neural Crest Stem Cells and Smooth Muscle Cells 
The Neural Crest is a source for different types of vascular smooth muscle cells. 
Some studies have propsosed that TGFβ1 has the ability to differentiate NCSC to a 
smooth muscle cell fate. Bergwerff et al 1995 conducted lineage tracing studies 
using quail-chick chimera techniques and found that NCSCs differentiated into 
SMCs and also into non musclular cells of the tunica intima and tunica media in the 
aortic arch. However, coronary and pulmonary arteries and the descending aorta 
showed no sign of SMC derived NCSCs (Bergwerff et al 1995). Neural crest cell 
importance to the vasculature is demonstrated by the fact that when a congenitatl 
malformation occurs involving the neural crest presents itself in severe 
cardiocascular abnormalities. It was demonstrated that the removal of the cardiac 
crest in chick embryos or the deletion of retenoic acid receptor genes cause severe 
malformations in embryological development such as, ventrical septal defects, 
common arterial trunk and aortic arch interuptions (Bockman et al. 1989; 
Mendelsohn et al. 1994). 
 Another example that emphasises a neural crest origin for vascular SMCs 
comes from a genetic study carried out on mice by (Epstein 2001). The failure to 
orchestrate neural crest development produced a phenotype that was reminiscnet of 
DiGeorge Syndrome, with symptoms including outlfow tract abnormalities and a 
reduction of smooth muscle in the proximal great vessels. 
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1.17 Expression markers associated with stem cells 
1.17.1 Multipotency markers associated with MVSCs 
Cells continually make decisions that determine their fate, whether it is migration, 
proliferation, apoptosis or self-renewal (in the case of stem cells). This fate is 
monitored by both intrinsic and extrinsic factors. Cell specific transcription factors 
have great influence over these decisions and serve to repress or activate different 
genes. Many different groups of factors have been identified, one of which includes 
the Sox proteins. Nanog, Oct4 and Sox2 pluripotency markers are well recognised as 
being associated with embryonic stem cells (Kashyap et al. 2009). However, markers 
associated with progenitor cells are less established. The panel of markers chosen to 
identify the MVSCs is a combination of Sox10, Sox17 and S100β. 
Sox proteins are a group of transcription factors found in all metazoan 
species (Wilson & Koopman 2002). These proteins hold various functions, playing a 
role in early development, organ formation and are also important for general 
maintenance within the cell, including self-renewal (Lefebvre et al. 2007). The Sox 
proteins regulate the transcription of certain genes by coordinating with other partner 
proteins; resulting in both gene-repression and gene-activation, depending on the 
type of interaction which occurs (Wilson & Koopman 2002).  
The first Sox gene to be identified was Sry which was discovered almost 23 
years ago. It is located on the Y chromosome and is responsible for determination of 
the male sex. It contains a conserved High Mobility Group (HMG) box domain. This 
domain is composed of 80 amino acids and has an affinity to 
5’(A/T)AACAA(T/A)3’ (Knower et al. 2003). Other proteins identified whose HMG 
domain have 50% or higher amino acid similarity to Sry are referred to as Sox (Sry 
related HMG Box) proteins, with corresponding genes termed “sox genes” (Lefebvre 
et al. 2007). Transcription can be activated by the HMG box via DNA binding 
activity but the non HMG domains can also play a role in partner protein selection 
and/or binding stability (Wilson & Koopman 2002). They can bind to all the minor 
grooves of DNA recognising the common motif sequence, it can also bend DNA and 
has therefore been linked to a role in assembly of transcriptional enhanceosomes. 
The Sox proteins are divided up into different groups (A-H) depending on their 
function (Table 1). Functions of each group may overlap. Within each group 70% of 
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the amino acids are common to one another. In contrast, those in different groups 
share very little similarity outside of their HMG domain (Lefebvre et al. 2007).  
 
Group Member(s) 
SoxA Sry 
SoxB2 Sox1, Sox2, Sox3 
SoxB2 Sox4, Sox11, Sox12 
SoxC Sox5, Sox6, Sox13 
SoxD Sox8, Sox9, Sox10 
SoxE Sox17, Sox7, Sox18 
SoxF Sox15 
SoxG Sox30 
SoxH Sox14, Sox21 
 
Table 1.0 Summary of Sox Proteins 
Sox activity varies from cell type to cell type and is also promoter dependent. Darby 
et al 2001 describe how Sox18 functions during embryonic development for 
endothelial differentiation and similarly holds a function by inducing angiogenesis 
during wound healing and tissue repair. Another example showing the variability of 
the Sox proteins is during neural crest development, the stages which Sox10, Sox9 
and Sox8 are expressed in mice, frog and chick embryos all differ from species to 
species (Hong & Saint-Jeannet 2005).  
The Sox proteins of interest here are Sox10 and Sox17, both of which are 
neural crest associated. Sox10 plays a role in neural crest development but has also 
found to be fundamental to neural crest survival (Paratore et al. 2001). It is suggested 
that Sox10 maintains multipotency and can inhibit differentiation of NCSC to a 
neuronal lineage (Kim et al. 2003). A study from (John et al. 2011), demonstrated 
that TGFβ1 mediated suppression of Sox10 induced a switch in neural potential 
favouring mesenchymal differentiation. It is suggested by (Corada et al. 2013) that 
Sox17 expression is exclusive to arteries and not found in veins. The expression of 
Sox17 is high in the mouse embryo and new borns with the expression being 
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retained in adult arteries. They also demonstrated that Sox17 acts upstream of Notch 
and downstream of the Wnt system. Abnormal pulmonary vascular morphogenesis 
which is linked to malfunctions within the postnatal cardiac phenotype, has been 
partly attributed to the deletion of Sox17 (Lange et al. 2014). Sox17 has also shown 
to be a fundamental component for the formation of the mesoderm in embryonic 
stem cells. RNA interference using short hairpin RNA (shRNA) inhibited the 
differentiation to cardiac counterparts in the primitive mesoderm (Liu et al. 2007). 
 S100β is a glial specific calcium binding protein with both intracellular and 
extracellular functions. Its expression is associated with the brain and cells such as 
astrocytes, oligodendrocytes and schwaan cells. It has also shown to play a role in 
the cardio vascular system, whereby it contributes to the left ventricle remodelling 
following myocardial infarction in mice (Tsoporis et al. 2005). The role of S100β in 
smooth muscle differentiation is not well understood.  
1.17.2  C-kit, Flt-1 and CD133 expression 
C-kit is a cytokine receptor that is also known as Cluster of Differentiation 117 (CD 
117). It is used to identify hematopoietic progenitor cells in the bone marrow (Fazel 
et al. 2006). It binds to stem cell factor also known as c-kit ligand and henceforth 
contributes to cell signalling by playing a role in cell survival, proliferation and 
differentiation (Matsui et al. 2004). Interestingly, (Hollenbeck et al. 2004) found 
there was an increase in c-kit expression in vascular lesions in rat balloon injury 
models. 
 Flt-1 is a receptor for Vascular Endothelial Growth Factor (VEGF). VEGF is 
important for vascular development and angiogenesis. It is normally associated with 
endothelial cells (Drake et al. 2000). It has been shown by (Orlandi & Bennett 2010) 
that blocking Flt-1 has an influence over several SMC functions including apoptotic 
susceptibility. Apoptosis was down regulated in balloon injury models which 
positively contributes to homeostasis within the vessel. Flt-1 expression was also 
found in human atherosclerotic lesions and restenoic lesions as well as in post injury 
rat aortic intimal thickening. However, there was no expression found in the normal 
tunica media. This might suggest that MVSCs express Flt1, but not adult SMCs. 
 CD133 is also known as Prominin. The function of this surface protein is not 
fully elucidated. CD133 is expressed in hematopoetic stem cells, endothelial 
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progenitors as well as neuronal and glial stem cells. In a study undertaken by (Adini 
et al. 2013), CD133 is shown to interact with VEGF. The knockdown model of 
CD133 caused disruption of capillary formation in vitro and decreased angiogenesis 
in vivo. Anti-CD133 has been added to stents to enhance endothelialisation (Li et al. 
2014). 
 
1.17.3 Nestin and Pax6 expression 
Nestin and Pax6 were used as markers to identify the NE4C cell line. Nestin is a type 
IV intermediate protein that can be found in neuronal (embryonic) progenitor cells 
and (Lendahl et al. 1990). It is found in early stage embryonic development of the 
Central Nervous System (CNS), Peripheral Nervous System (PNS) and in myogenic 
tissue. It is also found to persist throughout development. Nestin expression has also 
been found in vascular endothelial cells at the proliferative (endothelial progenitors) 
stage but not the mature vasculature.  Nestin is a good marker for undifferentiated 
cells of the CNS as the loss of the protein indicates commitment of the progeny to 
another specific lineage (Suzuki et al. 2010). Pax6 is a transcription factors and is 
associated with a member of a family of transcription factors. Pax6 is required for 
embryonic development of the central nervous system, the eye and the pancreas 
(Tyas 2003). There is less information in the literature regarding Pax6 expression 
and smooth muscle cells in the vasculature, but it has been shown that Pax6 may 
play a role in the development of smooth muscle in the iris (Jensen 2005). 
 
1.18 The induction of Smooth Muscle Cell differentiation in vitro 
1.18.1 TGFβ1 
TGFβ1 (Transforming Growth Factor Beta-1) is the founding member of the TGFβ 
super family. This family is made up of a number of different members including 
Activins, Bone Morphogenic Proteins (BMPs) and growth and differentiation 
factors, as well as other TGFβ counter parts (Massagué 1998). Different isoforms of 
TGFβ have been identified in mammals these are TGFβ1, TGFβ2 and TGFβ3. The 
isoforms carry out similar functions in a variety of cellular activities including 
growth, differentiation, proliferation, apoptosis and ECM synthesis in both ECs and 
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SMCs (Dennler et al. 2002; Schuster & Krieglstein 2002). Vascular smooth muscle 
cells express distinct TGFβ receptors in culture, two types exist, TGFβ type I 
receptor and TFGβ type II receptor. TGFβ is found in large amounts in platelet 
granules and has been found to play a role in wound healing. These two factors 
demonstrate how TGFβ can contribute to vascular biology (Goodman & Majack 
1989). 
 
1.18.2 TGFβ1 and smooth muscle cell differentiation 
TGFβ plays an important role in the differentiation of SMCs during embryonic 
development. (Perrella et al. 1998), discuss how TGFβ plays a role in blood vessel 
development during embryogenesis but also is vital for a variety of other vascular 
functions after developmental stages. For example, failure of SMC differentiation 
has been associated with a loss of TGFβ signalling components. This leads to 
abnormalities in the maturation of the vascular network (Goumans & Mummery 
2000). TGFβ is fundamental for controlling contraction, regulating blood pressure 
and is responsible for blood flow in postnatal development (Owens 1995). TGFβ can 
be PDGF (Platelet Derived Growth Factor) dependent and independent in 
stimulating SMC proliferation (Mallat et al. 2001). TGFβ and Notch activation have 
been shown to up regulate SMC genes and protein expression in SMC differentiation 
of Mesenchymal stem cells and human embryonic stem cells (Kurpinski et al. 2010). 
Moreoever, vascular SMCs have been derived from human pluripotent stem cells via 
neuroectodermal and mesodermal intermediates by use of TGFβ (Cheung et al. 
2012). 
1.18.3 The role of TGFβ in SMC related disease 
Studies from (Yamamoto et al. 2000; Orlandi et al. 1994) have shown that over 
expression of TGFβ increases SMC proliferation and differentiation, this has been 
shown to contribute to neointimal formation in balloon injury models. TGFβ has 
been directly linked with atherosclerosis, whereby it initiates the response of SMCs 
within the injured tissue or vessel (Lusis 2000). It has also been shown to affect the 
properties and the function of other cell types that are found in atherosclerotic 
lesions including; ECs, monocytes, platelets, T-cells and myofibroblasts (Bobik 
2006; Mallat & Tedgui 2002). Studies carried out in humans have shown that genetic 
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mutations in genes from the TGFβ family (or effector genes working 
upstream/downstream of TGFβ signalling) can lead to vascular dysfunction and 
disease, for example, Camurati-Engelmann disease which affects humans. A murine 
knock out model for the disease shows embryonic lethality with vascular defects or a 
post natal lethality from auto immune disease (Kulkarni et al. 1993). Research has 
indicated that TGFβ has a protective role by exertion of anti-atherogenic effects 
(Grainger 2004). It has been suggested that this is done by regulation of SMC 
proliferation or by anti-inflammatory functions it carries out (Mallat & Tedgui 
2002). More recently, elevated levels of TGFβ/Smad3 have been shown to contribute 
to Intimal Hyperplasia by inhibiting the apoptosis of SMCs through a mechanism 
involving VEGF (Shi et al. 2014). 
1.18.4 TGFβ and Smad protein signalling 
Members of the TGFβ family work by stimulating the formation of specific 
heteromeric complexes of type I and type II serine/threonine kinase receptors 
(Moustakas & Heldin 2005). The intracellular effectors of TGFβ signalling are the 
Smad proteins. These proteins were first identified in Drosophila and C.elegans 
(Patterson & Padgett 2000; Whitman 1998). They are expressed throughout 
embryonic development and they persist into adult life (Flanders et al. 2001; Luukko 
et al. 2001).  
 Cells can have two types of receptors as previously described; Type I and 
Type II. Together they form a heterodimer structure. TGFβ/Smad signalling is 
initiated when TGFβ ligand comes into contact with the receptor. The receptor is 
phosphorylated and the intracellular part of the TGFβ molecule becomes activated. 
This causes the phosphorylation of Smad2/3 protein. Smad4 then joins to 
phosphosmad2/3 forming a Smad complex. This activated complex can then travel 
to the nucleus where it can act as a transcription factor (Figure 1.7). The heterodimer 
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receptor can be activated by different ligands including Activin or BMP. The result 
of the ligand-receptor bond will depend on the initial activator and/or the stage of 
development (Moustakas & Heldin 2005). TGFβ specifically is associated with SMC 
signalling and vascular development (Whitman 1998). 
 
Figure 1.7 TGFβ and Smad2/3 signalling (Wilson Lab). 
 
Aims of the study: 
 
• To isolate multipotent vacsular stem cells (MVSC) from primary rat aortic 
medial explants. 
 
• To characterise MVSCs in culture for their multipotent properties via 
trilineage differentiation assays and by probing the cells for markers 
associated with neural stem progenitors, such as Sox10, Sox17, S100β and 
also the cluster of differentiation markers linked to MSC phenotype (CD44, 
CD29 and CD146). 
 
• To define MVSC transition to SMC lineage following treatment with TGF-
β1 and PDGF-BB. 
 
• To determine whether aortic SMCs in culture shared MVSC multipotent 
properties and/or phenotypic characteristics. 
 
• To determine whether an immortalised murine neuroectodermal progenitor 
stem cell line, NE-4C mimcked the multipotent properties and phenotypic 
characteristics of MVSC and further whether they transition and differentiate 
to SMC following TGF-β1 and PDGF-BB treatment. 
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Chapter 2: 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  31	  
	  
1.0 Materials 
	  
All materials used in the following experiments were of the highest purity and grade 
available. 
	  
ATCC 
A10 rat aorta, thoracic/medial layer (CRL 1476),  
A7r5 rat aorta, thoracic/smooth muscle (CRL 1444),  
NE4C mouse neural stem cell/brain/neuroectodermal (CRL 2925),  
Embryonic qualified FBS (30-2020),  
EMEM (30-2003) 
 
BD Biosciences 
BD Cytofix/Cytoperm™ Fixation/Permeabilization Solution Kit # 554714 
 
Fannin 
4 X SDS Laemmli Buffer (161-0747) 
 
Gibco 
B27 (17504-044) 
 
IDT 
Primer Sets 
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Invitrogen (Groningen, The Netherlands) 
Murine Mesenchymal Stem Cells (H+L) (S1502-100) 
Alexa Fluor® 546 Goat anti-rabbit (H+L) (A-11035) 
Alexa Fluor® 546 Goat anti-mouse (H+L) (A-11030) 
Alexa Fluor® 488 Goat anti-rabbit (H+L) (A-11008) 
Alexa Fluor® 488 Goat anti-mouse (H+L) (A-11001) 
Alexa Fluor® 488 Donkey anti-goat (H+L) (A-11055) 
N2 supplement (A13707-01) 
StemPro® Adipogenesis Differentiation Kit (A10070-01) 
StemPro® Osteogenesis Differentiation Kit (A10072-01) 
Cell Start (A10142-01) 
2-mercaptoethanol 50mM solution, (31350-010) 
DEPC treated water (750024) 
HCS Lipotox, (750024) 
 
InvivoGen 
Primocin (ant-pm-1) 
 
Millipore 
LIF (ESG1107) 
 
MP Biomedical (CA, USA) 
Chick embryo extract (2850145) 
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MSC 
Magcore cartridges total RNA Cultured Cells 610 (MRC-01 // MRC-02) 
Sensi-fast SYBR No-Rox one step kit (BIO-72005 ) 
 
PeproTech 
TGFβ1, PDGF-BB 
 
Pierce 
Dnase I,Rnase-free (89836) 
BCA Assay kit (23227) 
Page ruler ladder (26620) 
 
Qiagen (West Sussex, UK) 
SMA: Mm_Acta2_1_SG (QT00140119) 
SM-MHCII isoform 1: Mm_Myh11_1_SG (QT01060843) 
SM-MHCII isoform 2: Mm_Myh11_2_SG (QT02327626) 
Smoothened: Mm_Smtnl2_1_SG (QT00126455) 
Calponin: Mm_Cnn1_1_SG (QT00105420) 
Sox10: Mm_Sox10_1_SG (QT00295204) 
Sox17: Mm_Sox17_1_SG (QT00160720) 
S100β: Mm_S100b_1_SG (QT00151536) 
GAPDH: Mm_Gapdh_3_SG (QT01658692) 
 
 
R&D Systems (Minneapolis, USA) 
rmFGF (3139-FB-025)  
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TGFβ1 (7666-MB-005/CF) 
 
Sigma-Aldrich (Dorset, UK) 
2-mercaptoethanol (M-7154) 
30% bis/acrylamide solution (A3699) 
Alizarin Red (A5533) 
Anti-goat 2° antibody, HRP conjugated (A5420) 
Anti-mouse 2° antibody, HRP conjugated (A5278) 
Anti-rabbit 2° antibody, HRP conjugated (A0545) 
APS (A3678) 
BSA (A4503) 
Collagenase (C6885) 
DMEM (D5796) 
DMSO (C6164) 
Elastase type III (E0127-5MG) 
Fatty acid free BSA (A7030) 
FBS (F9665) 
Gel Blotting Paper (Z698172) 
Glycine (G8898) 
L-Glutamine (G7513) 
Oil Red O (O0625) 
Pen-Strep (P4333) 
Poly-L-Lysine (P9155) 
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Ponceau S stain (P7170) 
Protease inhibitor (P8340) 
Protran membrane (Z670979) 
Retinoic acid (R2656) 
RIPA (R0278) 
Soybean Trypsin inhibitor (T6414) 
TEMED (T7024) 
TMB (T0565) 
Triton X-100 (T8787) 
Trypan Blue (T8154) 
Trypsin (T4174) 
Tween (P1379) 
α-MEM (M0644) 
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2.1 Methods 
2.2 Cell culture protocols 
All cell culturing techniques were carried out in aseptically in a Biosciences Air 
2000 Mac laminar flow cabinet. Cells were maintained in a Hera water jacketed cell 
culture incubator at 37°C and 5% CO2. Cells were visualised using a Nikon Eclipse 
TS100 phase-contrast microscope. 
 
2.2.1 Embryonic Vascular Smooth Muscle cell culture 
Two embryonic smooth muscle cell lines were studied; A10 and A7r5. The cells 
were derived from rat embryos and were isolated from the thoracic aorta/medial 
layer and thoracic aorta/smooth muscle, respectively. A10 cells were cultured in 
Embryonic Stem Cell approved medium and 10% (v/v) Fetal Bovine Serum (FBS) 
supplemented with 1% Penicillin-Streptomycin (P/S), 0.001% of Leukemia 
Inhibitory Factor (LIF) and 0.01% of β mercaptoethanol (50mM). A7r5 cells were 
cultured in DMEM medium supplemented with 10% FBS and 1% P/S. For 
experimental purposes cells were cultured in T25cm2, T75cm2 and 6 well plates. 
 
2.2.2 Rat Mesenchymal Stem Cell Culture 
Rat Mesenchymal Stem Cells were used at low passages between 4 and 11. Low 
passages were used to ensure the cells still had high mulipotent potential. The cells 
were maintained in growth media made up of 50:50 minimal essential medium (α 
MEM) an Ham’s F12 supplemented with 10% MSC defined FBS, 150unit/ml 
penicillin and 150µg/ml streptomycin. 
 
2.2.3 NE4C Cell Culture 
NE4C cells were maintained in media as recommended. The media was composed of 
10% FBS embryonic qualified in EMEM. The media contained an initial 2mM L-
Glutamine and was supplemented with an extra 2mM of L-Glutamine to give a final 
concentration of 4mM in the maintenance media. Before NE4C cells were seeded 
onto plates/dishes the surface of the container was pre-coated with 15µg/ml Poly-L-
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Lysine. The plates were pre-coated and left to dry for 5 minutes. After this they were 
washed briefly with water and left to dry for at least 2 hours before the cells were 
seeded. 
 
2.2.4 Adult Smooth Muscle Cell line Culture 
Rat, mouse and bovine adult smooth muscle cell lines were cultured in 10% FBS and 
DMEM supplemented with 1% P/S. The cells were used up to passage 20. Murine 
aortic SMCs were obtained from ATCC Rockville, MD [MOVAS (ATCC CRL-
2797)]. Rat aortic SMCs [rSMCs, R354-05a) were obtained from Cell Applications, 
CA. Bovine aortic SMCs were obtained from Coriell Cell Repositories [Coriell 
AG08504, NJ, USA]. 
 
2.2.5 Isolation of Rat MVSC 
Male Sprague Dawley rats were anesthetized with pentobarbital sodium (0.1mg/g) 
and then perfused with 10ml of PBS. The ribcage was cut open at the front of the 
animal to expose internal organs. These were removed so the back of the ribcage was 
in view. The aorta was carefully excised using a tweezers and a scissors. The 
tweezers was carefully run along the side of the aorta to loosen it from the back 
bone. The aorta tissue was harvested as fast as possible from the lower thoracic aorta 
to the upper abdominal aorta. Following this, the tissue was briefly washed in cold 
PBS to remove any blood an excess fatty tissue. It was then placed in pre-warmed 
DMEM supplemented with 1% FBS and 1% P/S. The endothelium was removed by 
gently scraping off the cell layer on the luminal surface using a sterile scalpel blade. 
The aorta was placed in an enzyme solution containing 2.5mg/ml of collagenase for 
20 minutes at 37°C. After, the adventitia was carefully removed using a forceps 
under a dissection microscope. The layer of the artery that remains is the tunica 
media only. This section was cut up into pieces measuring 1mm in diameter. The 
tissue sections were placed on 6-well plates which were pre-coated with 1% 
CellStart (Invitrogen). Approximately 5-6 pieces of tissue were added per well. The 
cell start was diluted 1:50 in in Dulbecco’s Phosphate Buffered Saline with calcium 
and magnesium.  
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Figure 2.0 The adventitia was carefully removed and peeled back to isolate the 
medial layer only. 
 
 
Figure 2.1 MVSC isolation protocol. A) The surrounding fatty tissue is removed, B) 
the endothelial layer is gently removed, after incubation with an enzyme cocktail the 
adventitial layer is removed, C) the medial layer is the only remaining layer, D) the 
tunica media is cut up into small pieces and 6-7 pieces of tissue are placed in a pre-
coated 6 well plate. 
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2.2.6 Explant cell culture 
The tissue pieces were initially grown in 10% FBS in DMEM supplemented with 1% 
P/S and primocin at 100ug/ml. After three days cells began to explant out of the 
tissue. Once this was observed the tissue pieces were removed. Each well was 
washed briefly and the media was replaced with a maintenance media specifically 
designed to keep the MVSCs in a multipotent state. The media used to maintain 
MVSC multipotency was made up in DMEM and supplemented with 2% chick 
embryo extract (MP Biomedical), 1% FBS, 1% N2 (Invitrogen), 2% B27 
(Invitrogen), 100 nM retinoic acid (Sigma-Aldrich), 50 nM 2-mercaptoethanol 
(Sigma-Aldrich), 1% P/S and 20 ngml−1 bFGF (R&D Systems). Cells were re-fed 
every 2-3 days and passaged every 3days depending on confluency (usually around 
70%). The cells had a very low adherence rate after trypsonization. 
 
Figure 2.2 An example of progenitor cells in culture explanting from isolated tissue 
(Smart and Riley, 2006). 
 
2.2.7 Isolation of Enzymatically digested SMCs 
The same procedure was used as described previously in order to isolate the aorta. 
This time the cells of interest are the majority of cells in tunica media rather than the 
minority of mulipotent cells which explant out first from the vessel. As previously 
described, connective and outer fatty tissue was removed from the vessel. The aorta 
was then left in a collagenase solution at 2.5mg/ml for 20 minutes at 37°C. After this 
treatment the adventitia was removed carefully using a fine forceps. The tunica 
media was then incubated in a solution containing 0.25mg/ml elastase,  0.7mg/ml 
collagenase, 0.4mg/ml Soybean trypsin inhibitor and 1mg/ml essentially fatty acid 
free BSA for 2 hours at 37°C. At 15 minute intervals the tissue was removed from 
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the incubator and vortexed for 20 seconds to promote the dissociation of cells from 
the tissue. After two hours media containing 10% FBS in DMEM was added to the 
tissue and enzyme solution to neutralize the actions of the enzymes. The subsequent 
solution was spun down at 200 xg for 5 minutes and re-suspended in media before 
being plated onto 6 well plates. The media used for these cells was DMEM 
supplemented with 10% FBS and 1% P/S. The cells were allowed to settle down for 
48 hours before the media was changed and before analysis. 
 
2.2.8 Trypsinisation of cells 
All cell lines used were adherent therefore trypsinisation was required to sub culture 
the cells. Trypsin is a proteolytic enzyme that detaches cells from the surface they 
are cultured onto. Briefly, growth medium was removed from flasks/culture dishes 
and the cells were washed twice in sterile PBS to facilitate the removal of α-2-
macroglobulin, a component of FBS which inhibits the action of trypsin. 1X trypsin 
was added to the flask which was then incubated at 37°C for 2-5 minutes (depending 
on cell type). Regular cell growth medium containing FBS was added to neutralise 
the cleaving action of the trypsin. Cells were harvested by centrifugation at 115 xg 
for 5 minutes at room temperature. Cells were re-suspended in the appropriate 
volume of growth medium and counted using a haemocytometer. Cells were split at 
different ratios according to the specifications of individual cell lines. 
 
 
2.2.9 Cell Counting 
After trypsinisation cells were re-suspended in media and counted using a 
haemocytometer to obtain the number of viable cells. A 20µl cell suspension was 
mixed gently at 1:1 with 20µl of Trypan Blue. 20µl of this suspension was added to 
the haemocytometer (Figure 2.3). Trypan blue will stain cells which are not viable 
due to their leaky membrane. Viable healthy cells do not take up the dye and will 
appear bright under the microscope in comparison to the dead cells. Four of the 
chambers were counted excluding any cells which touched the line indicating the left 
side of the square and the top side of the square.  
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The cell number was calculated using the formula: 
(Cell Number)/4 * (Dilution Factor) * 1x104 
(area under cover slip mm) = Number of viable 
cells/ml 
 
 
Figure 2.3 Haemocytometer cell counting 
 
2.2.10 Cryogenic preservation and recovery of cells 
Cells were stored in cryovials suspended in Liquid Nitrogen at -196°C for long term 
storage. Cells were trypsinised and pelleted as per usual and re-suspended in freeze 
down media which was composed of 20% (v/v) FBS and 5% (v/v) DMSO in regular 
growth medium supplemented with 1% (v/v) P/S. Cells were divided into 1 ml 
aliquots in sterile cryovials. They were then placed in the Liquid Nitrogen cell and 
were frozen at the rate of –1°C/minute using a Mr Freeze® cryofreezing container.  
The cells were left in the -80°C freezer overnight and then transferred to a cryo-
freezer unit. 
 
2.3 Immunocytochemistry 
Cells were seeded at low density (5-10,000 cells/well) for immunocytochemistry to 
allow for clear visualisation of the cells. They were seeded onto 6 well plates 
containing sterile coverslips. Coverslips were sterilized in IMS for 2 hours and 
washed up to 5times in sterile PBS before the addition of cells. 
For preservation and fixation of samples cells were treated with 
formaldehyde at 3.7% for 15 minutes at room temperature. For intracellular staining 
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cells were permeabilized for 10-15 minutes using 0.025% Triton X-100. The 
samples were blocked for non-specific binding sites using 1ml of blocking buffer 
which was added to each well. The blocking solution was composed of 5% BSA and 
0.3M glycine in 1% Tween PBS solution. Samples were incubated for 1 hour at RT. 
The primary antibody was diluted in blocking buffer at the appropriate concentration 
and added to the coverslips. It was allowed to bind overnight at 4°C protected from 
the light. The secondary antibody was diluted in the blocking buffer at the 
appropriate concentration (Alexa Fluor 1:1000), added to the wells and incubated for 
1hr at room temperature. Cell nuclei were stained using DAPI (1:1000) and 
incubated for 15 minutes at room temperature. For each secondary antibody used a 
no primary control was prepared to ensure that there was no non-specific binding of 
the secondary antibody to the cells (Figure 2.4). All of the secondary alone controls 
can be found in the Appendices. Cells were washed in between each step using 1% 
Tween in PBS 2-3 times for five minutes, with gentle agitation. Exposure to light 
was minimal throughout the process. 8-10 images were taken per sample at 
magnifications of 10X, 20X and 60X or 100X power. Results are representative of 
experiments that were repeated multiple times (n=3 or more). 
 
A   B  
Figure 2.4 Sample immunocytochemistry images of cells probed with primary and 
secondary antibody and DAPI (A) and cells probed with secondary antibody and 
DAPI (B) - primary antibody control. Cells shown here are MVSCs expressing 
Sox10. DAPI stain used for neucli observation. 
 
2.4 Confocal Imaging 
Cells were plated onto glass coverslips and placed in six well culture plates. The 
cells were incubated for at least 48 hours, allowing the cell attachment and spreading 
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for optimal protein visualisation. Before probing the cells with antibody they were 
fixed and permeabilized using ice-cold acetone for 1 min. The cells were then 
washed three times with PBS containing 0.5% TWEEN-20. Non-specific binding of 
the antibody was prevented by blocking the cells in a solution of 5% BSA made up 
in PBS containing 0.5% Tween-20 for ten minutes at room temperature. Specific 
primary antibodies were added to the cells and they were incubated overnight at 4°C. 
The following day the appropriate secondary Alexa 488-labelled antibody was added 
to the samples and the cells were incubated at room temperature for 60 minutes. The 
coverslips containing the cells were mounted onto slides with antifade medium 
(Dako). Slide preparations were observed using a Zeiss Axio Observer. Z1 equipped 
with a Zeiss 710 and ConfoCor3 laser scanning confocal head (Carl Zeiss, Inc.). 
Images were analyzed using Zen 2008 software (Figure 2.5). 8-10 images were 
taken per sample at magnifications of 10X, 20X and 60X or 100X power. All results 
shown are representative of experiments that were repeated multiple times (n=3 or 
more). Secondary controls were used for all samples. 
A   B  
Figure 2.5 Sample confocal images of cells probed with primary and secondary 
antibody (A) and cells probed with secondary antibody only (B) - primary antibody 
control. Cells shown here are MVSCs expressing SMA. 
 
2.5 SDS-PAGE and Western Blot Analysis 
2.5.1 Preparation of Whole Cell Lysates – Protein Harvest 
Protein samples were harvested using radioimmunoprecipitation assay (RIPA) lysis 
buffer (composed of; 20mM Tris, 150mM NaCl; 1mM Na2EDTA; 1mM EGTA; 1% 
Triton X-100 (v/v); 2.5mM sodium pyrophosphate; 1mM-glycerophosphate; 1mM 
sodium orthovanadate; 1µg/ml leupeptin) supplemented with protease - phosphate 
inhibitor cocktails (1/100 dilution of each, Sigma Aldrich). Cells were washed 2-3 
	  44	  
	  
times in ice cold PBS. A small volume of ice-cold PBS was added to each well and a 
cell scraper was used to detach the cells from the plate surface. The cells were 
collected and centrifuged for ten minutes at 1000rpm to pellet the cells. The PBS 
was removed and an appropriate volume of RIPA buffer (depending on 
pellet/samples size) was added to the pellet to lyse the cells. The amount added was 
minimal to ensure a high concentration (mg/ml) of protein was achieved. The cell 
lysate suspension was re-suspended in the RIPA buffer using a pipette to ensure 
equal mixing and yielding the maximum amount of protein from the cells. The tubes 
were sonicated for 10 seconds at 40% using a Branson Digital Sonifier (AGB 
Scientific). The samples were either stored at -80°C (long term), -20°C (short term) 
or used immediately in a BCA assay to determine the overall protein concentration 
or for western blot analysis. 
 
2.5.2 Preparation of fractionated Lysates 
Protein was isolated in the same manner as whole cell lysates. After suspension in 
RIPA buffer the cells were kept on ice for an hour. Every ten minutes the samples 
were vortexted for 10 seconds. The samples were then spun down at 13,000rpm for 
10 minutes at 4°C. The supernatant was removed, representing the cytosolic fraction 
and the pellet (nuclear fraction) was re-suspended in a defined quantity of RIPA 
buffer and sonicated to release any membrane bound proteins. The fractions were 
either used immediately for Western Blot analysis or stored at -80°C. 
 
2.5.3 Protein Sonication 
Protein sonication agitates the samples using sound energy. The purpose of this is to 
release any membrane bound proteins from the nuclear fraction or total protein 
lysate. This was carried out for 10-15 seconds depending on the viscosity/size of the 
cell lysate/pellet at 40%. 
 
2.5.4 Bicinchoninic acid (BCA) Assay 
The Bicinchoninic acid (BCA) protein microassay is a method used for protein 
quantification. Cell lysates were analysed using a commercially available “Pierce 
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BCA Protein Assay Kit” to determine the total protein concentration per sample. The 
assay uses the Biuret reaction and protein concentration is determined 
calorimetrically using a colour change approach. The assay depends on selective 
calorimetric detection of Cu+ ions by the bicinchoninic acid (BCA). Cu2+ reacts with 
protein under alkaline conditions and is reduced, producing the cuprous cation (Cu+), 
with selective colorimetric detection of Cu+ using a reagent containing BCA. 
Bicinchoninic acid, sodium salt, is a stable water-soluble compound that forms a 
purple complex (originally yellow/green) with cuprous ions in an alkaline 
environment. The complex formed exhibits strong absorbance at 562nm and is 
measured using a spectrophotometer (Thermo Scientific). The absorbance is linear 
with increasing protein concentrations from standards ranging between 0.2-2mg/ml. 
Protein lysates and the bovine serum albumin (BSA) protein standards were added to 
a 96 well plate in triplicate (10µl). The kit supplies two different solutions A and B. 
A is an alkaline bicarbonate solution and B is a copper sulphate solution. A dilution 
of 1:50 is made by mixing B:A. 200µl of this solution was added to the protein cell 
lysate or BSA protein standard. The plate was protected from light and incubated at 
37°C in a CO2 incubator for 30 minutes. A standard curve was prepared using BSA 
(0-2mg/ml) for each experiment and from this the protein concentrations were 
determined quantitatively (Figure 2.6). 
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Figure 2.6 Example of BCA assay standard curve to determine protein 
concentration. 
 
2.6 Western Blotting 
SDS-PAGE was performed as described by Laemmli using 12.5%, 7.5% and 5% 
polyacrylamide gels (Laemmli et al., 1970). The semi-dry Western blot method was 
used. The gels (stacking and resolving) were prepared as follows: 
 
Resolving Gel: 
Component 7.5% 12.5% 
30% bis/acrylamide solution 
(ml) 
1.875 3.12 
1.5M Tris-HCl pH8.8 (ml) 1.875 1.875 
10% SDS (µl) 75 75 
dH2O (ml) 3.63 2.38 
10% APS (µl) 37.5 37.5 
TEMED (µl) 7.5 7.5 
 
Table 2.1 SDS PAGE Resolving Gel recipe  
y	  =	  0.4171x	  +	  0.1451	  
R²	  =	  0.98709	  
0	  
0.2	  
0.4	  
0.6	  
0.8	  
1	  
1.2	  
0	   0.5	   1	   1.5	   2	   2.5	  
AB
S	  
Concentra-on	  mg/ml	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Stacking Gel (5%):  
30% bis/acrylamide (µl) 325 
1M Tris-HCl (µl) 625 
10% SDS (µl) 25 
dH2O (ml) 1.54 
10% APS (µl) 12.5 
TEMED (µl) 5 
 
Table 2.2 SDS PAGE Stacking Gel recipe  
 
 For analysis of cell lysate protein concentration was determined using the 
BCA assay as described previously. From this equal amounts of protein were added 
to each well in the gel. Before addition to the gel the samples were mixed with a 4X 
laemmli loading buffer (8% SDS, 20% β-mercaptoethanol, 40% glycerol, Brilliant 
Blue R in 0.32M Tris pH6.8). The samples were boiled for 5 minutes at 95 °C and 
immediately placed on ice. The gel electrophoresed in reservoir buffer (0.025M Tris 
pH8.3; 0.192M Glycine; 0.1% (w/v) SDS) at 30mA using a power pack (BioRad). 
Pierce page ruler ladder was used as a marker for protein size, 10µl of the ladder was 
added to the appropriate well. The gel was pre run for 30 minutes before the samples 
were added, upon addition of the samples the gel was run until the dye front reached 
the bottom of the gel. 
 Following gel electrophoresis the gel was soaked in transfer buffer (0.025M 
Tris pH8.3; 0.192M Glycine; 15% v/v methanol) for 10 minutes at 4°C. For each gel 
one sheet of Whatman (Life Sciences) nitrocellulose membrane was cut and 6 sheets 
of Whatman gel blotting paper (Sigma) were cut to fit the size of the gel and pre-
soaked in transfer buffer. Proteins were transferred to the membrane using an Atto 
gel box (MSC) semi-dry automated system for 30 minutes at 17V. Ponceau S 
staining was used to confirm the transfer of the proteins from the gel to the 
membrane. The Ponceau S stain was left on the blots for 2-3 minutes and washed 
briefly using dH2O revealing defined pink bands demonstrating the transfer of the 
proteins (Figure 2.7). Once protein transfer was confirmed the blots were blocking in 
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a blocking buffer (0.5% BSA and 0.1% Tween in PBS) for one hour at room 
temperature on agitation. Following the blocking step, blots were probed with the 
appropriate antibody at the appropriate concentration overnight at 4°C. The next day 
the blot were washed three times for five minutes each with 0.1% Tween. The 
appropriate HRP-conjugated secondary antibody was added to the blots for 2 hours 
at room temperature, away from light with gentle agitation. Both primary and 
secondary antibodies were diluted in blocking buffer solution. After the incubation 
the washing step was repeated on the blot.  The blot was washed as before and 5ml 
of 3, 3’,5,5’-Tetramethylbenzidine (TMB) was added to each blot to determine if the 
desired protein was present on the blot. The protein bands will appear within minutes 
displaying a dark blue colour on the blot. dH2O used to wash off the TMB and stop 
the further development of non-specific bands/background staining. TMB is a 
chromogenic substrate that allows for the visualisation of the protein bands when 
used for the western blot method (Figure 2.8). Adobe software and densitometry was 
used to analyse the blots. GAPDH or β-Actin (depending on the experiment) primary 
antibodies were used for each blot as a loading control as well as the Ponceau S 
stain. 
 
A    B  
Figure 2.7A Example of Ponceau S staining protein on blot, Figure 2.7B protein 
ladder used for molecular weight marker. 
 
	  49	  
	  
 
Figure 2.8 Representative western blot of smooth muscle actin in MVSCs. 
Visualisation was carried out using TMB after secondary antibody incubation. 
 
 
2.6.1 Antibody Dilutions 
Primary 
Antibody 
Dilutio
n 
Secondary Antibody Dilution  
CNN1  
(Sigma) 
1:5000 HRP-Conjugated Anti-mouse IgG 1:5000 
αActin 
(Sigma) 
1:5000 HRP-Conjugated Anti-mouse IgG 1:5000 
SM-MHCII (1) 
(Abcam) 
1:1000 HRP-Conjugated Anti-rabbit IgG 1:5000 
SM-MHCII (2) 
(Sigma) 
1:1000 HRP-Conjugated Anti-mouse IgG 1:5000 
SM-MHCII (3) 
(Santa Cruz) 
1:1000 HRP-Conjugated Anti-goat IgG 1:5000 
Sox17 
(Millipore) 
1:2000 HRP-Conjugated Anti-rabbit IgG 1:5000 
Sox10 
(Abcam) 
1:2000 HRP-Conjugated Anti-rabbit IgG 1:5000 
S100β 
(Millipore) 
1:2000 HRP-Conjugated Anti-rabbit IgG 1:5000 
SMAD3 1:5000 HRP-Conjugated Anti-rabbit IgG 1:5000 
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(Abcam) 
GAPDH 
(Sigma) 
1:5000 HRP-Conjugated Anti-rabbit IgG 1:5000 
Β-Actin 
(Sigma) 
1:5000 HRP-Conjugated Anti-mouse IgG 1:5000 
 
Table 2.3 Outline of antibody dilutions used in experiments 
 
2.7 Flow Cytometry 
Flow Cytometry is a method used in biotechnology and other industries to count and 
sort cells. FACSTM (Fluorescent Activated Cell Sorting) is a type of flow cytometry 
whereby cell samples flow through the cytometer in a single cell fluid suspension. 
Cell samples are treated with flouresecent particles in preparation for this method of 
analysis. Particles which can be used include Annexin V and Alexa Fluor 488/546 
for example. The cytometer contains a laser which analyses the particles as they pass 
by. This laser measures the forward scatter and side scatter of the cells analysing the 
size of the cell and granularity of the cell respectively. The laser measures these 
parameters based on fluorescence of each individual cell as it passes a certain point. 
The fluorescent particles are excited at a certain wavelength and then emit at another 
wavelength depending on each individual particle. For example Alexa Fluor 488 
excites at 499nm and emits and 519nm. There are filters in front of the detectors in 
the cytometer that restrict the light that reaches the detector to a specific range of 
wavelengths.  
 
2.7.1 Protein Marker Analysis 
FACS was used to screen a series of cell lines for different markers representing 
smooth muscle and stem cell phenotypes. The kit used was BD Bioscience 
Cytofix/Cytoperm and the protocol provided was used. Briefly, 500,000 cells were 
used per sample (equal cell number). After the cells were pelleted they were fixed (if 
appropriate for the antigen) using BD cytoperm solution for 20 minutes at 4°C. 
Following two brief wash steps the appropriate primary antibody was added at a 
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final concentration of 1µg per sample. The cells were incubated at 4°C for 30 
minutes. The cells were washed again and incubated with appropriate secondary 
antibody (Alexa Fluor 488 or Alexa Fluor 546) for 30 minutes at 4°X. Cells were 
analysed using BD FACS Calibur using the corresponding detector according to the 
secondary fluorescent probe used (Figure 2.9). 
 
A.   B.  
Figure 2.9 Example of FACS data analysis. A) Secondary antibody control, B) 
MVSC expression of CNN1. 
 
2.7.2  FACS Data Analysis 
Data analysis was performed using FloJo and De Novo software FCS Express 4 
Flow Cytometry. 
 
2.8 Polymerase Chain Reaction (PCR) 
2.8.1 Preparation of total RNA 
RNA was isolated from cultured cells using the MagCore® HF16 System of RBC 
Bioscience Corp. (Figure 2). This instrument purifies Nucleic acids (RNA and 
DNA) from many different tissue types, but for the purpose of these experiments kit 
no. 610 was used for RNA extraction. The kit is a cartridge that contains different 
solutions/buffers pre-prepared that are required for the isolation of RNA [Figure 
2.3]. These cartridges are slotted into racks within the machine. Two sets of racks 
are within the machine, the smaller T-rack holds the samples and buffers prepared by 
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the user and the second larger rack hold the pre-prepared cartridges. Pipette tips are 
added to well 2 and the machine picks up the raw sample and extracts the RNA 
allowing everything to be carried out in a controlled, sterile environment. The 
instrument provides a protocol for tissue processing and this was followed. Briefly, 
Cells were trypsinised from 6-well plates and washed once using PBS. A Reaction 
Buffer supplemented with 1% β-mercaptoethanol was prepared and 200µl of this 
solution was added to the cell pellet.  The cell and buffer solution and mixed using a 
vortex until the cell pellet was re-suspended. This suspension was added to well 4 on 
the rack. A DNase solution was prepared using DNase I and a DNase buffer solution 
provided and this was added to well 3 (Figure 2.10). The 610 option program was 
run and the total duration for pure RNA extraction was 73 minutes. Samples were 
eluted in 60µl of DEPC treated water into an elution tube inserted to Well 1. 
 
  
 
	  53	  
	  
 
 
Figure 2.10 Magcore components A) T-rack for holding samples and DNase 
solution. B) Magcore instrument. C) Pre-prepared cartridge of solutions. 
 
2.8.2 RNA Measurement 
2.8.3 The NanoDrop® ND-1000 Spectrophotometer 
The NanoDrop® ND-1000 Spectrophotometer (Thermo Scientific) was used to 
determine the concentration of mRNA in the samples obtained from the Magcore. 
2µl of DEPC treated water was used as a blank before measuring protein samples. 
2µl of sample was pipetted onto the end of a fibre optic wire. The second fibre optic 
wire was brought forward so it was in contact with the sample as well. The liquid in 
between the two fibres bridges the gap closing up the system. A pulsed xenon flash 
lamp provides the light source and a spectrophotometer using a linear charged 
coupled device (CCD) array analyses the light after passing through the sample. The 
	  54	  
	  
NanoDrop® automatically calculates the purity of the mRNA sample added by 
taking two absorbance readings at 260nm and 280nm and determining the ratio 
between them. Pure RNA should have a ratio of 2.0. A lower ratio may indicate 
phenol or another contamination that is absorbed at 280nm. The NanoDrop® also 
takes readings at 230nm and calculates a 230nm:260nm ratio which is a second ratio 
indicator of RNA purity. These values can be higher than the 260/280 ratios but are 
generally between 2.0-2.2. If the ratio is lower this may indicate the presence of a 
contaminant that absorbs at 230nm. The instrument is connected to a PC and 
controlled by specialised software. Samples are analysed in triplicate and kept on ice 
at all times.  
 
2.8.4 Primer Sets 
Primer sets were purchased from Qiagen and IDT, as outlined in materials and 
methods. A SYBR no-ROX master mix was used with the primers. 
 
2.8.5 Real time qRT-PCR 
Quantitative PCR was carried out using a Real Time Rotor-GeneRG-3000TM 
lightcycler (Corbett Research). This type of PCR is a more accurate method of 
quantification in comparison with older gel based methods. All components needed 
for this reaction are contained within the one tube. The principle behind this method 
is that the amount of fluorescence measured is directly related to the product 
amplification and this is proportional to the amount of target gene present in the 
sample (Figure 2.11). 
This method is used to quantify specific RNA target amplifications using the 
designated primer sets. This procedure permits for streamlined samples and allows 
for higher throughput analysis, whereby reverse transcription and PCR take place 
sequentially in the same reaction tube. The kit used was QuantiTect SYBR Green 
PCR kit. The kit contains a master mix which contains; SYBR Green dye (the 
fluorescent component for the detection of the amplicon), a SYBR Green buffer 
containing a balanced combination of K+ and NH4+ ions (encouraging specific 
primer annealing) and Taq polymerase. The kit also supplies reverse transcriptase 
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which is added to the sample reaction tubes only. Samples were prepared in triplicate 
with reverse transcriptase and a control sample for each sample was set up excluding 
the reverse transcriptase. GAPDH was used as the reference “house keeping” gene 
for comparison for all reactions. 
Component Sample + Reverse 
Transcriptase 
Sample – Reverse 
Transcriptase 
RNA (10ng) 5µl 5µl 
Primer 2.5µl 2.5µl 
Rnase free H2O 4.75µl 5µl 
SYBR Green 12.5µl 12.5µl 
RT 0.25µl - 
 
The program used on the instrument for the different primer sets were as follows: 
Denaturing Phase 95°C - 20s 
Annealing Phase 55-60°C - 30s (55 cycles) 
Elongation Phase 72°C - 30s 
 
The results obtained were analysed using the Comparative CT method 
(ΔΔCT), described by Livak and Schmittgen, 2001. 
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Figure 2.11 Example of qRT-PCR output data. Curved lines indicate +RT samples 
and straight lines indicate –RT controls. 
 
2.9 Cell manipulations 
2.9.1 Serum Deprivation 
Where appropriate for marker/phenotype analysis cells were serum deprived. This 
was done by using 0.5% FBS in DMEM supplemented with 1% P/S. 
 
2.9.2 Adipogenesis Differentiation 
StemPro® Adipogenesis Differentiation Kit (Invitrogen) was used to differentiate 
multiple different cell lines to test their stem like properties, including A10, A7r5, rat 
derived multipotent vascular stem cells and rat mesenchymal stem cells. Arterial 
derived rat vascular smooth muscle cells were used as a control. Briefly, cells were 
cultured in 12 well plates to 60-80% confluency. Media provided with the kit was 
added to the cells once they were ready. The transformation took between 7-14 days. 
Cells were fixed and stained using a 0.5% Oil Red O solution (Sigma) to determine 
if the differentiation to an adipocyte cell took place. A fluorescent stain HCS 
lipidTOX was used to confirm the adipocyte differentiation results 
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2.9.3 Oil Red O Stain Preparation 
300mg of oil red O powder was added to 100ml of 99% isopropanol. In the fume 
hood 30ml of the oil red o stock was added to 20ml of deionized water. The solution 
was sterile filtered using a 0.2µM filter. After fixation of the cells were washed three 
times in deionized water.  2ml of 60% isopropanol was then added to cells for 2 
minutes. The cells were washed briefly again in PBS and the working concentration 
solution of oil red o was added, ensuring the cells were fully covered with the dye. 
The samples were left at room temperature for 15 minutes. After the incubation the 
cells five times in deionized water ensuring that most of the stain had been removed. 
The cells were then analysed using an Olympus CK30 microscope under phase 
contrast (Figure 2.12). 
A      B  
Figure 2.12 Example of rMSC transition to adipocyte, visualisation under phase 
contrast using A) Oil Red O staining and B) LipidTox fluorescent staining 
 
2.9.4 HCS LipidTox 
HCS LipidTox was applied to the cells after fixation at a concentration of 200X. The 
cells were incubated for at least 30 minutes before visualisation. The fluorescent dye 
was visible under the 488 (green) filter on the microscope. 
 
2.9.5 Osteogenesis Differentiation 
StemPro® Osteogenesis Differentiation Kit (Invitrogen) was used to differentiate 
A10, A7r5, MVSC, MSC, rSMC cell lines as described in the manual. Mesenchymal 
stem cells served as a positive control for the differentiation process. The cells were 
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plated at a density of 10 x103 cells/cm2 and were left to grow for 2 days before the 
addition of the osteogenic supplement. Cells were left to grow for 21 days, the media 
was replenished every 3 days. After 21 days the cells were stained for Calcium 
deposits using Alizarin Red Dye. Large red globular structures were observed where 
differentiation had occurred.  
 
2.9.6 Alizarin Red Dye 
Alizarin red dye was prepared to a concentration of 2% in dH2O. The pH of the dye 
was adjusted to 4.1-4.3 if required using NH4OH. Afterward, the dye was filtered 
using a 0.45µ pore filter. After cell fixation the cells were stained with alizarin red 
dye and incubated for 10-15 minutes at room temperature. The cells were washed 5 
times and left in PBS for analysis. The samples were visualised under Nikon 
microscope using phase contrast. Mineralized tissue nodules form where the 
differentiation has taken place. These calcium deposits will stain bright red/orange 
(Figure 2.13). 
 
Figure 2.13 Example of rMSC transition to osteocyte, visualisation under phase 
contrast using Alizarin Red staining method. 
 
2.10 Data Anlaysis 
Results are expressed as mean ± SEM. Experimental points were performed in 
triplicate, with a minimum of three independent runs. A t-test was used for 
comparison of two groups. A value of p≤0.05 was considered significant. For 
immunocytochemistry and confocal imaging the stain intensity and location was 
analysed. 
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Results 
Chapter 3: 
Multipotent Vascular Stem Cell 
Isolation and Characterisation 
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3.0 Introduction 
As previously described the topic of SMC infiltration in vascular remodelling is 
highly controversial at the moment (Tang et al 2012, Nguyen et al 2013). The latest 
population of cells proposed to be involved with intimal lesions and subsequent 
disease progression are resident multipotent vascular stem cells (MVSCs). They 
were originally isolated from the medial explants of rat tissue but other studies have 
encountered cells with related properties within the adventitia of both arterial and 
venous vessels from both animals and humans (Gallagher et al. 2000; Owens et al. 
2004; Tang et al. 2012; Gomez & Owens 2012).  MVSCs are derived from the 
neural crest and therefore co express markers associated with this phenotype; S100β, 
Sox10 and Sox17. In culture these cells have been found to poorly express SMC 
differentiation markers CNN1 and especially SM-MHCII. When these cells are 
treated with TGFβ1 they transition to SMCs and begin to express SMC 
differentiation markers (Wang et al 2012). It is hypothesized that under injury in 
vitro these cells transition to MSC-like cells and subsequently to SMCs, contributing 
to vascular remodelling (Wang et al 2012, 2013). 
 For the purpose of this study a population of MVSC cells were isolated from 
rat medial aortic tissue using the explant method. The cells were screened for panels 
of markers associated with SMCs [SMA, CNN1, SM-MHCII], MVSCs [Sox10, 
Sox17, S100β] and MSCs [CD29, CD44, CD146]. The cells were also treated with 
induction media for osteocyte and adipocyte lineage differentiation. Adult rat SMCs 
and Rat MSCs were used as appropriate controls for all experiments investigating 
the characteristics and phenotype of the MVSC cell line. 
 
3.1 Materials and methods 
All materials used were of the highest purity available commercially. Primary cell 
culture was carried out as previously described in Chapter 2 using the explant 
method. Protein analysis was carried out using FACS, western blotting, 
immunocytochemistry and confocal imaging. The cells were treated with induction 
media for adipogenic and osteogenic differentiation as previously described. MVSCs 
were also treated with TGFβ1 and PDGFBB for smooth muscle cell differentiation.  
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3.2 Cell lines and Reagents 
A primary cell line was generated by explant method using rat aortic tissue. The cells 
were taken from the medial layer of the aorta. The cells were grown in a 
maintenance media as previously described. The first set of cells that explanted from 
the tissue were the multipotent Vascular Stem Cell (MVSC) population. These are 
the resident stem-like cells present in the medial tissue possessing characteristics 
associated with multi-potent stem cells. These cells were immediately grown in a 
specific maintenance media (previously described). Once isolated these cells were 
cultured and used for experiments up to Passage 8. In a parallel experiment the 
medial layer of the aorta was digested in enzymes collagenase and elastase. Both cell 
lines were analysed for MVSC and SMC marker expression. Enzymatically 
dissolved cells were only screened briefly. This was to confirm the hypothesis that 
the cells explanting first off the tissue are those with multipotent properties and the 
majority of cells remaining in the tissue do not possess stem cell characteristics. 
Therefore for the purpose of this work the cell line that was of main focus was the 
MVSC cell line. 
 
3.3 MVSC appearance phase contrast 
MVSCs were observed under the light microscope. Their appearance was slightly 
different to that of Bovine aortic Smooth Muscle Cells (BaSMCs). Although both 
cell lines were elongated, MVSCs displayed narrower spindles. When confluent they 
grew at a fast rate in comparison with SMCs and their growth pattern was one 
presenting star-like arrays as opposed to the hill and valley growth pattern of SMCs 
(Figure 3.0). 
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Figure 3.0 Phase contrast images of BaSMCs and rMVSCs. Cells were fixed in 
3.7% formaldehyde and observed under phase contrast on the microscope for 
visualisation. 
 
3.4 Expression of Sox10 and SM-MHCII proteins in situ 
Collaborators that also worked on this project freshly isolated aortic tissue from 
murine source. Protein isolates were made and analysed for the presence of Sox10 
and SM-MHCII. For comparison, protein isolates from cultured human SMC were 
ran in parallel. Sox10 expression was found to be very low in the aortic tissue, in 
comparison with the smooth muscle cells that showed high expression. SM-MHCII 
was very highly expressed in the fresh vessel with a lower amount found in the 
cultured smooth muscle cells (Figure 3.1). Tang et al 2012 completed a similar study 
whereby they found very little Sox10 expression via in situ analysis yet the cells they 
explanted from the same tissue were all Sox10 positive. These results led to the 
isolation of an MVSC population and further analysis on their Sox10 and SM-
MHCII expression was investigated (Tang et al 2012). 
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Figure 3.1 The expression of Sox10 and SM-MHCII in fresh vessel lysates and a 
human smooth muscle cell line were evaluated using a western blot. Lysates and 
analysis were carried out by collaborators on this project (Kennedy et al 2014). 
3.5 Sox10 and SM-MHCII expression in MVSCs 
Following the isolation of the MVSC population, their characterisation was very 
important before these cells could be used in any differentiation experiments. The 
isolated population needed to be deemed multipotent not only for differentiation 
experiments but also to confirm the hypothesis that the correct population of cells 
had been isolated from the tissue. The explanted MVSC cells were characterised 
extensively using immunocytocehemistry, FACS and western blot for protein 
analysis. The multipotent markers used included S100β (astrocyte marker), Sox10 
(neural stem cell marker) and Sox17 (endoderm marker) (Tang et al 2012). These 
markers are known as stem/pluripotent markers therefore the presence of these 
markers indicated that the population of cells isolated were of stem cell origin. 
Sox10 and SM-MHCII expression were the two first important proteins to be 
analysed. The cells expressed the nuclear Sox10 protein and a small amount of 
cytoplasmic expression was found (Figure 3.2). The cells were negative for SM-
MHCII with no filaments visible and very little fluorescent staining found (Figure 
3.3). A double stain was carried out to show the two markers together in one cell that 
represents the MVSC population Sox10+/SM-MHCII- (Figure 3.4). The cells 
expressed SM-MHCII via FACS and this raised confusion as the immune data was 
negative. Western blot data confirmed that the antibody was non specific and also 
picked up on SM-MHCI (Figure 3.5). The absence of the late SMC marker SM-
MHCII shows that these cells do not represent a differentiated contractile phenotype. 
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The presence of sox10+/SMA+/SM-MHCII- cell showed that this cell population 
stemmed from smooth muscle origin, and was not defined as an adult contractile cell 
line due to the absence of smooth muscle myosin heavy chain II.  
 
Figure 3.2 MVSCs in maintenance media stained immunocytochemically for Sox10. 
Cells were fixed using formaldehyde and stained for the respective stem cell marker 
using primary antibody. Cells were probed with an appropriate secondary antibody 
and stained with DAPI for nuclei visualisation. Scale Bar indicates 50nm. 
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Figure 3.3 MVSCs stained immunocytochemically for SM-MHCII. Cells were fixed 
using formaldehyde and stained for the respective stem cell marker using primary 
antibody. Cells were probed with an appropriate secondary antibody and stained 
with DAPI for nuclei visualisation. Scale Bar indicates 50nm. 
Figure 3.4 Sox10/SM-MHCII double stain on MVSCs. Cells were seeded at a low 
density (5,000 cells/well) and incubated for 48 hours before probing with the 
appropriate primary and secondary antibody. Scale Bar indicates 50nm. 
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Figure 3.5 FACS analysis of Sox10 and SM-MHCII on MVSCs. Cells were prepared 
as required for FACS analysis. Protein expression of the markers can be seen in red 
with secondary controls in black. The shift in peak indicated protein expression. 
 
3.6 Cellular localisation of Stem Cell Markers 
MVSCs protein analysis was carried out using immunocytochemistry, FACS and 
western blotting for neural stem cell marker Sox17 and glial cell marker S100β after 
Sox10 expression was confirmed. The cells expressed both proteins. Images for 
immunocytochemistry were taken and both high and low power lens (Figure 3.6). 
FACS confirmed the expression of these markers (Figure 3.7). Western Blots were 
performed on lysates for MVSCs and the membranes were probed for Sox17 
(44kDa), Sox10 (49Dka) ans S100β (11kDa) (Figure 3.8). 
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Figure 3.6 MVSCs stained immunocytochemically for Sox17 and S100β. Cells were 
fixed using formaldehyde and stained for the respective stem cell marker using 
primary antibody. Cells were probed with an appropriate secondary antibody and 
stained with DAPI for nuclei visualisation. Scale bar indicates 50nm for all images. 
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Figure 3.7 FACS analysis of Sox17, S100β and SSEA-1 (Stage Specific Embryonic 
Antigen1) on MVSCs. Cells were prepared as required for FACS analysis. Protein 
expression of the markers can be seen in red with secondary controls in black. The 
shift in peak indicated protein expression.  
 
 
Figure 3.8 Western Blot analysis of multipotent markers Sox10, Sox17 and S100β. 
Cells were seeded at a density of 100,000 cells per well and left incubated for at 
least 48 hours before protein isolation was carried out. Samples were probed with 
appropriate primary and secondary antibodies and finally TMB for colorimetric 
analysis. 
 
3.7 Cellular localiasation of smooth muscle cell markers in MVSCs 
Although the MVSCs posess stem cell markers, it was important to analyse the cell 
line for smooth muscle cell markers since they were derived from smooth muscle 
tissue. These cells were generated to be used as a differentiation model of stem cells 
to smooth muscle cells, therefore before any treatment of the cells it was of great 
importance to establish the basal line expression of SMC markers in the population. 
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Apart from SM-MHCII expression as already discussed the two other markers used 
were SMA and CNN. These three markers as a team cover late (SM-MHCII), middle 
(CNN1) and early (SMA) stage differention of smooth muscle cells (Campbell et. al 
1979). Using this panel allowed the assessment of how far along the differentiation 
pathway the MVSCs were. Immunocytochemically, the generated cell line was 
positive for SMA and CNN1 (Figure 3.9), which has been previously described 
(Wang et. al 2012). The population showed that some cells had not yet begun to 
express Calponin 1. This phenotype is associated with a more juvenile SMC 
population. Cultured smooth muscle cells derived from rat and murine sources were 
used as positive controls for the smooth muscle cell markers. Confocal (murine) and 
immunofluorescence (rat) techniques were used (Figure 3.10, 3.11). FACS analysis 
was used to compliment the immunocytochemistry data to show SMA and CNN1 
positivity (Figure 3.12). This method gives insight into a larger population of cells as 
it analysis 10,000 cells/count in comparison with ICC which captured tens of cells 
per frame. Lysates isolated from MVSCs were probed against SMC markers SMA, 
CNN1, SM-MHCII (Figure 3.13). Protein analysis showed that MVSCs expressed 
SMA and CNN1 but did not show any SM-MHCII expression, the bands that 
appeared were specific to SM-MHCI indicating that MVSCs express some amount 
of SM-MHCI. 
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Figure 3.9 SMA and CNN1 protein expression in MVSCs grown in maintenance 
media. Cells were seeded at a low density (5,000 cells/well) and incubated for 48 
hours before probing with the appropriate primary and secondary antibody. Scale 
bar represents 50nm for all images. 
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Figure 3.10 Immunocytochemistry of rat SMC expressing SMC markers in 
differentiation media [SMA, CNN1, SM-MHCII]. Cells were seeded at a low density 
(5,000 cells/well) and incubated for 48 hours before probing with the appropriate 
primary and secondary antibody. Scale bar indicates 50nm for all image 
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Figure 3.11 Murine SMC grown in differentiation media expression of smooth 
muscle cell markers SMA, CNN1, SM-MHCII. Cells were seeded at a low density 
(5,000 cells/well) and incubated for 48 hours before probing with the appropriate 
primary and secondary antibody. 
 
 
Figure 3.12 FACS analysis of SMA and CNN1 for MVSCs. Cells were prepared as 
required for FACS analysis. Protein expression of the markers can be seen in red 
with secondary controls in black. The shift in peak indicated protein expression. 
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Figure 3.13 Representative immunoblot of SMC differentiation markers [SMA, 
CNN1, SM-MHC] on MVSCs. Cells were seeded at a density of 100,000 cells per 
well and left incubated for at least 48 hours before protein isolation was carried out. 
Samples were probed with appropriate primary and secondary antibodies and 
finally TMB for colorimetric analysis 
 
3.8 Expression pattern of enzymatically digested SMCs from rat aortic 
medial layer 
As described previously, two different populations were isolated. Firstly, those cells 
which migrated off the explant tissue in early days and secondly the media vessel as 
a whole after enzymatic digestion. Both cell populations were characterised at P1 
using immunocytochemistry for SM-MHII and Sox10. The cells were analysed using 
an Olypmus BX51 microscope at low power X 20 and X 100 magnifications. The 
purpose of this experiment was to show that not all cells in the medial layer present 
the Sox10+/SM-MHCII- phenotype and that these characteristics only apply to a 
small percentage of the cells in the tissue ie the resident stem cell population. 
The enzymatically digested SMCs were highly positive for SM-MHCII in 
comparison with the MVSCs (Figure 3.14, 3.15). Myosin filaments were clearly 
visible at low and high power magnifications in enzymatic SMCs. There was a small 
amount of staining in the MVSCs at high and low power magnification but this 
appears to be non-specific binding of the primary antibody as the small amount of 
staining was not uniform between different samples/images.  
Sox10 protein is a nuclear protein. MVSCs stained strongly positive for 
Sox10 in the nucleus as predicted. In comparison, the enzymatically digested SMCs 
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had very low Sox10 staining in the nucleus with a small amount of staining seen in 
the cytoplasm (Figure 3.14, 3.15). 
  
 
 
Figure 3.14 Freshly isolated enzymatically digested SMC in differentiation media 
expression of SM marker SM-MHCII and Neural stem cell marker Sox10. Cells were 
at a low density (5,000 cells/well) and incubated for 48 hours after all tissue was 
removed. Samples were then probed with the appropriate primary and secondary 
antibody. Scale bar represents 50nm for all images 
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Figure 3.15 Freshly isolated MVSC in maintenance media expression of SM marker 
SM-MHCII and Neural stem cell marker Sox10. Cells were at a low density (5,000 
cells/well) and incubated for 48 hours after all tissue was removed. Samples were 
then probed with the appropriate primary and secondary antibody. Scale bar 
represents 50nm for all images 
3.9 Mesenchymal Stem Cell Marker expression in MVSCs 
MVSCs expression of mesenchymal stem cell markers CD29, CD44 and CD146 was 
determined using immunocytochemistry (Figure 3.16). Rat mesenchymal stem cells 
were used as a positive control for this assay. FACS analysis was used to confirm the 
presence of CD29 and CD44 in MVSCs (Figure 3.17). 
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Figure 3.16 Immunocytochemical data for MVSC expression of MSC markers 
[CD29, CD44, CD146]. Rat MSC used as positive control. Cells were seeded at a 
low density (5,000 cells/well) and incubated for 48 hours before probing with the 
appropriate primary and secondary antibody. Scale bar represents 50nm for all 
images. 
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Figure 3.17 FACS analysis for CD29 and CD44 in MVSCs. Cells were prepared as 
required for FACS analysis. Protein expression of the markers can be seen in red 
with secondary controls in black. The shift in peak indicated protein expression. 
 
3.10 Expression of neural and glial stem cell markers in rat Mesenchymal 
Stem cells. 
Rat MSCs were analysed for the presence of the three stem cell markers associated 
with MVSCs (Sox10, Sox17, S100β) (Figure 3.18). This was carried out to monitor 
the transition of MVSC differentiation to MSCs. It was hypothesized that MSCs 
would still retain some of these stem cell markers in culture, to fit in with the profile 
of MVSC differentiation to MSC and finally to SMC. MSCs are the intermediate cell 
type and could possibly still retain some of the MVSC properties. 
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Figure 3.18 Rat MSC expression of markers associated with MVSC phenotype 
[Sox10, Sox17, S100β]. Cells were seeded at a low density (5,000 cells/well) and 
incubated for 48 hours before probing with the appropriate primary and secondary 
antibody. Scale bar represents 50nm for all images. 
 
3.11 Differentiation potential of MVSCs 
In order for this isolated cell population to be considered stem cell like, the cells 
must retain some (as much as possible) of the multipotent traits associated with stem 
cells. Multipotent stem cells should be capable to differentiate into bone, muscle, fat, 
cartilage and other tissues. Smooth muscle cell potential of the MVSC population 
was shown firstly using high serum concentration (10%) to examine spontaneous 
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differentiation and then the use of TGFβ1 and PDGFBB for induced SMC 
differentiation.  
 
3.12 Smooth Muscle Cell differentiation of MVSCs 
Two different methods were used to investigate the differentiation of MVSCs to 
SMCs. The first was using media containing 10% Fetal Calf Serum (FCS) in regular 
DMEM which was also carried out by Tang et. al 2012 The second was using 
TGFβ1 and PDGFBB in media containing 5% serum. In a parallel experiment 
MVSCs were cultured continuously for 3 weeks in 10% FCS DMEM media. Each 
experiment involved the assessment of smooth muscle cell markers and/or stem cell 
markers. Expression of SMA was already apparent in MVSCs. The treatment with 
differentiation media slightly increased fluorescent intensity but overall there was no 
huge change in expression. CNN1 expression increased over the ten day stimulation. 
To begin with there was a small population of CNN1- cells, after treatment the cells 
all expressed some levels of CNN1. SM-MHCII expression was slightly increased 
but there were no myosin filaments observed (Figure 3.19). 
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Figure 3.19 SMC marker expression after 10 days in 10% FCS DMEM 
differentiation media. Cells were seeded at a low density (5,000 cells/well) and 
incubated for 10 days in media containing 10% FCS. The media was replenished 
every 2-3 days. The cells were fixed in formaldehyde and treated with the 
appropriate primary and secondary antibodies. Scale bar represents 50nm for all 
images. 
 
3.12.1 Protein expression analysis after 21 day serum induction 
MVSCs were screened for the late SMC marker, SM-MHCII expression after culture 
in differentiation media for 21 days (Figure 3.20). The presence of this marker 
would indicate SMC differentiation. MVSCs reached Passage 14. Stem cell markers 
were maintained after 10 days in differentiation media so these markers (Sox10, 
Sox17, S100β) were further analysed the MVSCs cultured for 21 days. MVSCs 
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started off with a Sox10+/Sox17+/S100β+/SMA+/CNN1+/SM-MHCII- phenotype. 
Following 21 days in culture it was found that the cells maintained their a 
Sox10+/Sox17+/S100β+/SMA+/CNN1+ expression and also became slightly SM-
MHCII positive in comparison with MVSCs in maintenance media as previously 
described. 
 
 
Figure 3.20 SM-MHCII, Sox10, Sox 17 and S100β expression in MVSCs after 21 
days culture in 10% FCS DMEM. Cells were seeded at a low density (5,000 
cells/well) and incubated for 21 days in media containing 10% FCS. The media was 
replenished every 2-3 days. The cells were fixed in formaldehyde and treated with 
the appropriate primary and secondary antibodies. Scale bar represents 50nm for 
all images. 
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3.12.2 Smooth Muscle Cell induction of MVSCs using TGFβ1and PDGFBB 
The activation of the TGFβ1 pathway is an established method of driving smooth 
muscle cell differentiation. Serum naturally contains some components that will 
initiate this therefore naturally MVSCs in serum will slowly become more smooth 
muscle cell like as they are passaged, as observed previously when cells were left for 
10 and 21 days in FCS. To achieve full differentiation of SMCs TGFβ1 was used.  
Two different concentrations were used to compare what dose of TGFβ1 was most 
effective in smooth muscle cell differentiation. Both 2ng/ml and 5ng/ml were used 
with the addition of 10ng/ml PDGFBB in each case. 5ng/ml gave greater 
differentiation and this was the concentration chosen for future experiments.  
The concentration of FCS is important for TGFβ1 activation. Too high a 
serum concentration can inhibit the action of TGFβ1, and too low of a concentration 
will mean that the cells cannot grow properly and the TGFβ1 may induce apoptosis. 
Optimal serum concentration was determined using immunocytochemistry. 
 
3.12.3 TGFβ1 optimisation in FCS 
In order to maximise cell growth in TGFβ1 the media in which the cells were grown 
in, the FCS concentration was optimised (Figure 3.21). Three different 
concentrations of FCS were used in parallel experiments; 2% FCS, 5% FCS and 
10% FCS (all in DMEM). The SMC differentiation marker examined was SM-
MHCII as it was the best indicator of smooth muscle cell differentiation. 
	  83	  
	  
 
Figure 3.21 Optimisation of FCS concentration for TGFβ1 differentiation of MVSC 
to SMC at concentrations of 2, 5, 10%. Cells were seeded at a low density (5,000 
cells/well) and incubated for 5 days in media containing either 2, 5 or 10% FCS. The 
media was replenished every 2-3 days. The cells were fixed in formaldehyde and 
treated with antibody against SM-MHCII antigen and the appropriate secondary 
antibody. Scale bar represents 50nm for all images. 
 
MVSCs were treated for 5 days with 5ng/ml TGFβ1 and 10ng/ml of PDGFBB in the 
different serum conditions. All three serum conditions stimulated MVSC 
differentiation. Cells at 2% FCS were shrunken, after fixation of the cells in 
formaldehyde the majority of the cells had lifted off. The low serum conditions had 
compromised their state. Cells treated in the differentiation media with 5% FBS were 
healthy and flattened. 10% serum treated cells were healthier than the cells in 2% 
serum but still appeared to be shrunken and elongated. Therefore, 5% serum was 
chosen as the optimal concentration for further analysis. Control samples containing 
just 2%, 5% and 10% FCS were run simultaneously (data not shown). 
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3.12.4 Expression of smooth muscle, neural and glial cell markers in MVSCs 
after TGFβ1 and PDGFBB treatment 
After optimisation of the TGFβ1, PDGFBB and FCS cocktail, further analysis was 
undertaken to investigate the expression of SMA and CNN1 SMC markers (other 
markers including Sox10, Sox17 and S100β) (Figure 3.22). As before rat smooth 
muscle cells were used as positive controls for immunocytochemistry analysis. 
Because MVSCs expressed SMA before any treatment it was not predicted that the 
SMA fluorescent intensity would increase. There was a slight increase in frequency 
of filaments but overall there was no huge change in SMA expression after TGF β1 
stimulation. After treatment with TGFβ1 and PDGFBB, MVSCs appeared to express 
increased levels of CNN. The staining was more intense in the treated samples and 
the filaments became more obvious indicating a mature smooth muscle cell 
phenotype. The induction of SM-MHCII was the most important result for this 
experiment. The MVSC cell population went from SM-MHCII- to SM-MHCII+. 
Analysis was under taken in high and low power magnifications. The staining was 
intense and myosin filaments were visible indicating that the cells had transitioned to 
mature SMCs.  
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Figure 3.22 SMA, CNN1 and SM-MHCII expression after TGFβ1 stimulation in 
MVSCs. Cells were seeded at a low density (5,000 cells/well) and incubated for 5 
days in media containing 10% FCS with differentiation components 5ng/ml TGFβ1 
and 10ng/ml PDGFBB. The media was replenished every 2-3 days. The cells were 
fixed in formaldehyde and treated with the appropriate primary and secondary 
antibodies. Scale bar represents 50nm for all images. 
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3.13 Osteocyte and Adipocyte differentiation 
The assays used here to determine the multipotency of MVSCs were an osteogenesis 
assay (bone cells) and an adipogenesis assay (fat cells). MVSC were prepared in 
parallel expriments and treated according to each protocol (Figure 3.23, 3.24). Rat 
mesechymal stem cells were used for both experiments as a positive control. Rat 
smooth muscle cells were used as a negative control. Untreated samples for each cell 
line were used as another control. Alizarin red (osteocyte) and Oil Red O (Adipocyte 
and LipidTox) stains were used for visualisation. Both treated and untreated samples 
were stained. The use of an untreated sample acted as an internal control and 
eliminated non-specific binding of the stains. MVSCs demonstrated SMC 
differentiation, Osteogenic differentiation and Adipogenic differentiation. There was 
a clear induction of osteocyte differentiation in both MVSCs and MSCs. Bright red 
calcium-rich deposits were observed in treated samples showing that differentiation 
has occurred. In adipogenic cultures red globular structured were found in samples 
treated with the induction media. The results from these differentiation assays 
indicated the multipotency of the cell line and the capability of this cell line to be 
used as an in vitro model for MVSC to smooth muscle cell differentiation. 
 
 
	  87	  
	  
 
Figure 3.23 Generation of osteocytes from MVSCs, rMSCs (positive control) and 
rSMCs (negative control). Cells were seeded at low density (5,000 cells/well) and 
treated for 21 days with osteogenic induction media. The samples were then stained 
using Alizarin Red dye to visualise differentiated osteocytes. Scale bar represents 
50nm for all images. 
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Figure 3.24 Differentiation of MVSCs, MSCs and rSMCs to adipocytes. Analysis 
carried out using both Oil Red O and a fluorescent LipidTox stain. Cells were 
seeded at low density (5,000 cells/well) and treated for 7-14 days with adipogenic 
induction media. The samples were then stained using Oil Red O dye/LipidTox 
fluorescent probe to visualise differentiated osteocytes. Scale bar represents 50nm 
for all images. 
 
3.14 Summary 
• A Multipotent Vascular Stem Cell population was generated by explant 
method (representing the stem-like population) from the tunica media of 
aortas isolated from Sprague Dawley rats. 
• MVSC appearance was more spindle-like and star shaped in comparison to 
adult bovine aortic SMCs that were used as a control. 
• MVSCs were characterised for stem cell like markers, of particular interest 
was Sox10, Sox17 and S100β. MVSCs were positive for these markers by 
immunocytochemistry, western blot and FACS analysis. 
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• MVSCs were also characterised for markers associated with smooth muscle 
cells [SMA, CNN1, SM-MHCII]. They were found to be SMA+/CNN1+/SM-
MHCII-. Adult SMCs were used as positive controls. 
• Cells enzymatically digested from the tunica media (representing the 
majority of cells in the vessel) were characterised for Sox10 and SM-MHCII, 
the cells displayed a Sox10+/SM-MHCII- phenotype. 
• The MVSCs were analysed for mesenchymal stem cell markers CD29 and 
CD44 to determine how much in common they have with their MSC 
intermediates. MVSCs were positive for both markers. 
• MVSCs were deemed multipotent by use of induction media to differentiate 
them to adipocytes and osteocytes in parallel experiments 
• After three weeks in a differentiation media (10% FBS in DMEM), MVSCs 
showed some evidence of SM-MHCII expression. This was noted by the 
increase in fluorescent stain. 
• MVSCs were treated with 5ng/ml TGFβ1and10ng/ml PDGFBB for 5days 
and were analysed for SM-MHCII using immunocytochemistry. The cells 
expressed high levels of SM-MHCII, indicating that smooth muscle 
differentiation had occurred. 
 
 
.  
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Chapter 4: 
Evaluation of Stem Cell markers in 
Embryonic and Adult SMC lines 
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4.0 Introduction 
A10 and A7r5 cell lines are embryonic cells lines that have been derived from the 
thoracic aorta of 14-17 day old embryonic BD1X rats. These cells are commonly 
used as representative models for vSMCs in cultures (Rao et al. 1997). The cell lines 
have been used in different studies relating to smooth muscle cell research (Zhou et 
al. 2010; D C Graves & Yablonka-Reuveni 2000; Capey et al. 2007); (Watanabe 
2002). Both cell lines are considered models of non-differentiated, neonatal and 
neotintimal vascular smooth muscle cells in culture. Initial studies carried out by Roa 
et al 1997 described the cells as non-differentiated SMCs, the research suggests that 
the cells differ from the neonatal cells but have a significant resemblance to 
neoinitmal cells. The functionality and relevance of A10 and A7r5 cells as 
representative model smooth muscle cell lines in research is questionable, 
specifically speaking, when used to identify mechanisms underlying the contractile 
properties of highly differentiated vascular smooth muscle cells. However, these cell 
lines still present an adult smooth muscle cell phenotype, showing protein expression 
and evidence of several highly restricted smooth muscle cell markers including SM 
CNN1, SM22 and to a lesser extent SM-MHCII (Firulli et al. 1998). Graves et al 
2000, carried out a detailed analysis of a gene expression program which reported a 
phenotypic transition of the cell lines from vascular smooth muscle to skeletal 
muscle, this research suggests that these cells may still retain multipotent and some 
stem cell like properties. The cells have been shown to contract by both calcium 
dependent and calcium independent mechanisms, a characteristic associated with a 
highly differentiated smooth muscle cell (Nakajima et al. 1993). 
 However, the actin cytomatrix of these cells shares structural similarities to 
fibroblasts, similar to other smooth muscle cell types that can revert back to 
presenting a less differentiated SMC phenotype when grown in culture. Despite this 
the cells are still used in research due to their apparent similarities to neointimal cells 
and they offer an excellent model for investigating transcriptional regulation of 
vSMC markers and signalling cascades involved in neointima formation (American 
et al. 1979; Rao et al. 1997; Firulli et al. 1998). 
More recently, multipotent vascular stem cells have been identified and 
characterised within adventitial and medial layers of the vessel wall. The transition 
of these cells and their response after injury is highly topical (Tang et al 2012, 2013). 
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It has been suggested that A10 and A7r5 cell lines that are defined as proliferative or 
synthetic SMCs due to their phenotype are in fact SMCs which have been derived 
from these resident stem cells in culture, as opposed to being de-differentiated 
immature/mature SMCs (Tang et al. 2012; Hu et al. 2004). This discovery of these 
resident progenitors prompted a re-evaluation of the origin and identity associated 
with these embryonic smooth muscle cell lines and to investigate whether or not 
these cells share properties associated with resident vascular stem cells in culture. 
The cell lines were analysed for stem cell markers associated with MVSCs [Sox10. 
Sox17, S100β], adventitial cell marker [Sca-1+], established smooth muscle cell 
markers [SMA, CNN1, SM-MHCII] and also analysed for their multipotent 
potential. 
It was of interest to investigate commercially available adult smooth muscle 
cell lines in culture and establish whether these SMC lines exhibit neural stem cell 
markers that are typical of MVSCs. Cell lines were murine, rat and bovine, 
interestingly isolated by different culture methods, enzymatic dispersal (murine and 
rat) and explant (bovine). SMC differentiation expression markers were analysed as 
well as neural stem cell marker expression and the multipotent capabilities of the 
adult SMC lines following lineage induction in vitro. 
 
4.1 Materials and Methods 
All materials used were of the highest purity available commercially. Cell culture 
was carried out as previously described in Chapter 2. Embryonic smooth muscle cell 
lines A10 and A7r5 were used in this chapter as well as commercially available adult 
smooth muscle cell lines from three different sources; Rat, Murine and Bovine. 
Serum deprivation for cellular manipulations was carried out using 0.5% serum 
containing media. Protein analysis was carried out using FACS, western blotting, 
immunocytochemistry and confocal imaging. Analysis of mRNA was carried out 
using qRT-PCR. The cells were treated with induction media for adipogenic 
differentiation as previously described.  
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4.2 Results 
MVSCs remained sox10, sox17 positive and concomitantly expressed SM-MHC 
after treatment in 10% DMEM as a differentiation media. For this reason A10 and 
A7r5 cell lines were screened with sox10 and SM-MHC antibodies to identify 
whether any ‘MVSC-like’ positive cells were present in the two populations.  
 
4.3 Cell lines and reagents 
The A10 cell line is a rat embryonic cell line derived from the aorta, thoracic/medial 
layer, similarly, A7r5 cell lines is a rat embryonic derived cell line from the aorta, 
thoracic/smooth muscle. Both cell lines were cultured in regular DMEM media 
supplemented with 10% FBS before phenotypic analysis. A10 cell line was 
supplemented with Leukemia Inhibitory Factor (LIF) and 2-Mercaptoethanol. The 
A10 cell line possess the typical myoblast morphology (Figure 4.0) and when grown 
in culture all cells screened positive for early, middle and late stage smooth muscle 
cell markers; smooth muscle α-actin, Calponin1 and SM-MHCII (Figure 4.1). This 
expression is indicative of their SMC traits. A7r5 cell line had a different 
morphology with a flat ribbon like structure growing in parallel arrays of spindle 
shaped cells when confluent (Figure 4.0). These cells were also positive for the three 
smooth muscle cell markers, yet in contrast to the A10 cell line there was a 
proportion of A7r5 cells that appeared to be weakly positive for SM-MHCII and 
CNN1 (Figure 4.2). Rat mesenchymal stem cells were used as positive controls for 
multipotency assays (adipogenesis and osteogenesis differentiation). These cells 
were maintained in growth media made up of 50:50  minimal essential medium (α-
MEM) and supplemented with 10% FBS. These cells were characterised for the 
expression of MSC markers using antibodies against CD29, CD44, CD90 and 
CD146. 
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Figure 4.0 Phase contrast images A10 and A7r5 Cell lines. Cells were seeded at a 
low density (5,000 cells/well) and fixed in 3.7% formaldehyde before visualisation 
under phase contrast. Scale bar represents 50nm for each image. 
 
4.4 Local expression of SMC markers in embryonic stem cell lines 
SMC protein expression [SMA, CNN1, SM-MHCII] was assessed using 
immunocytochemistry. This was carried out initially before any further experiments 
to characterise the expression of these proteins in the cell lines. Cells were seeded at 
low density (5,000 cells/well) for visualisation and left for 3 days before being 
probed with antibodies. Nuclei were stained with DAPI. Both A10 and A7r5 cell 
lines expressed all three markers. Some cells were found to be slightly more CNN1 
positive. This phenotype is representative of a SMC that is not fully differentiated. 
Flow Cytometry was used as a second method of protein expression to  reaffirm 
results that were achieved with immunocytochemistry (Figure 4.3, 4.4). 
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Figure 4.1 A10 expression of SMC markers [SMA, CNN1, SM-MHCII], confocal 
and flourescent microscpe images. Cells were seeded at a low density (5,000 
cells/well) and incubated for 72 hours before probing with the appropriate primary 
and secondary antibody. Scale bar represents 50nm for all images. 
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Figure 4.2 A7R5 expression of SMC markers [SMA, CNN1, SM-MHCII], confocal 
and flourescent microscpe images. Cells were seeded at a low density (5,000 
cells/well) and incubated for 72 hours before probing with the appropriate primary 
and secondary antibody. Scale bar represents 50nm for all images. 
 
 
Figure 4.3 SMC protein expression in A10 via FACS [CNN1, SM-MHCII]. Cells 
were prepared as required for FACS analysis. Protein expression of the markers can 
be seen in red with secondary controls in black. The shift in peak indicated protein 
expression. 
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Figure 4.4 SMC protein expression in A7r5 via FACS [CNN1, SM-MHCII]. Cells 
were prepared as required for FACS analysis. Protein expression of the markers can 
be seen in red with secondary controls in black. The shift in peak indicated protein 
expression. 
 
4.5 Evaluation of the MVSC Sox10+/SM-MHCII- population in embryonic 
cell lines 
The desired cell population according to Tang et. al 2012 would be a smooth muscle 
precursor cell that expresses neural stem cell marker Sox10 and lack the expression 
of differentiated SMC marker SM-MHCII. MVSCs were characterised using a 
double stain for these two proteins, for this reason the same experiment was carried 
out on A10 and A7r5 cell lines (Figure 4.5). 
 
Figure 4.5 Double Stain on A10 and A7r5 for Sox10 and SM-MHCII. Cells were 
seeded at a low density (5,000 cells/well) and incubated for at least 48 hours before 
probing with the appropriate primary and secondary antibody. Scale bar represents 
50nm for all images. 
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4.6 Expression profile of neural and glial cell markers in A10 and A7r5 cell 
lines 
A10 and A7r5 both represent embryonic cell lines. It was hypothesized that these 
cell lines may retain some of the stem cell like properties, including expression of 
stem cell markers. MVSCs which had been analysed as previously described were 
used as positive controls. The cell lines were analysed using immunocytochemistry 
and FACS analysis (Figure 4.6 & 4.7). Both cell lines were also screen for Stem Cell 
Antigen 1 (Figure 4.8). This marker is associated with stem cells in the adventitial 
layer of the smooth muscle vessel. The cell lines A10 and A7r5 were more than 
likely generated by enzymatic dispersal of the full vessel. It was highly likely that 
the cells would retain this stem cell associated marker as well as continual 
expression of the markers associated with the medial layer. In contrast to A10, A7r5 
cells stained poorly for SM-MHC by ICC yet the shift in FACS data showed that the 
cells display a SM-MHC phenotype. Like the A10 cells the A7r5 cells stained 
strongly for the neural stem makers Sox10, Sox17 and S100β. A7r5 cells stained 
positive for Sca1+ by both FACS and by immunocytochemistry.  
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Figure 4.6 A10 immunocytochemical expression of MVSC markers [Sox10, Sox17 
and S100β]. Cells were seeded at a low density (5,000 cells/well) and incubated for 
at least 48 hours before probing with the appropriate primary and secondary 
antibody. Scale bar represents 50nm for all images. 
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Figure 4.7 A7r5 immunocytochemical expression of associated stem cell markers 
[Sox10 and Sox17]. Cells were seeded at a low density (5,000 cells/well) and 
incubated for at least 48 hours before probing with the appropriate primary and 
secondary antibody. Scale bar represents 50nm for all images. 
 
 
Figure 4.8 A10 and A7r5 Sca1+ expression using immunocytochemistry. Cells were 
seeded at a low density (5,000 cells/well) and incubated for at least 48 hours before 
probing with the appropriate primary and secondary antibody. 
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Figure 4.9 Stem cell marker (neural and glial) protein expression on A10 cells 
[Sox10, Sox17, S100β and Sca1+]. Cells were prepared as required for FACS 
analysis. Protein expression of the markers can be seen in red with secondary 
controls in black. The shift in peak indicated protein expression. 
 
 
Figure 4.10 Stem cell marker (neural and glial) protein expression on A7r5 cells 
[Sox10, Sox17, S100β and Sca1+]. Cells were prepared as required for FACS 
analysis. Protein expression of the markers can be seen in red with secondary 
controls in black. The shift in peak indicated protein expression. 
 
4.7 Relative protein expression levels of Sox10, Sox17, S100β, CNN, SMA 
and SM-MHCII. 
Further protein analysis on A10 and A7r5 was carried out using immublotting. 
MVSC cells were used as a positive control for the stem cell markers [Sox10, Sox17 
and S100β] and SMC markers [SMA and CNN1] (Figure 4.11). Maximum amount 
of protein was added to each well. β-Actin was used as a loading control as well as 
Ponceau S. stain. 
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Figure 4.11 Western Blot analysis of Sox10, Sox17, S100β, SMA, CNN1, SM-MHCII 
on A10 and A7r5 cell lines, MVSCs acting as positive control. Cells were seeded at a 
density of 100,000 cells per well and left incubated for at least 48 hours before 
protein isolation was carried out. Samples were probed with appropriate primary 
and secondary antibodies and finally TMB for colorimetric analysis. 
 
4.8 Cell Manipulations 
4.8.1 Expression analysis after quiescence of A10 and A7r5 Cell lines 
When SMC in culture are quiesced via serum deprivation, SMC differentiation is 
increased and can be measured by increase in SMC marker expression; SMA, 
CNN1, SM-MHC.  A10 and A7r5 cells were quiesced for 72 hours and compared to 
untreated serum containing samples. Following the quiescence A10 and A7r5 cells 
phenotypic changes in the expression of SMC markers SMA and CNN1 was 
analysed using confocal microscopy. With regard to the A7r5 cell line there was a 
clear redistribution of SMA and CNN1 filaments after the 72h serum deprivation in 
comparison with regular serum conditions (Figure 4.12). A clear reorganization of 
actin filaments can be seen under serum conditions in comparison with serum 
deprived cells. The serum deprived cells overall have a lower intensity of staining. In 
comparison with serum deprived cells the filaments are less visible with a higher 
staining intensity being visible at the periphery. With regard to CNN1, the intensity 
of the stain is increased in serum deprived conditions and there is a presence of 
filaments which cannot be found in cells cultured in full serum.  
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A10 cell line showed a similar pattern whereby the expression of CNN1 and 
SMA increased when the cells were serum deprived. There was an overall increase 
in fluorescent intensity in samples which were quiesced (Figure 4.13). The actin 
filaments were much more pronounced in these samples in comparison with the 
serum containing samples. 
The effect of serum deprivation on rat MSC was investigated in order to see 
how MSCs respond in comparison with the embryonic A10 and A7r5 cell lines. 
MSCs were seeded at low density (5,000 cells/well) and quiesced for 72 hours. 
Smooth muscle actin was chosen as the SMC differentiation marker of choice, an 
increase in SMC markers such as SMA is associated with MSC to SMC 
differentiation (Figure 4.14). 
There was a clear rearrangement of actin filaments after serum deprivation. 
rMSCs in 5% media displayed a lower range of fluorescence and there were fewer 
filaments observed with most of the staining on the periphery of the cells. In 
comparison serum deprived cells displayed much greater staining and an increase in 
the presence of filaments. The full circumference of the cell displayed the spindle 
like filaments. SMCs were cultured in 5% FBS and used as an indicator for the MSC 
differentiation. From the images it is clear that the SMA phenotype of the serum 
deprived MSCs is very similar to that of the adult smooth muscle cells. 
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Figure 4.12 Confocal immunocytochemical of SMC differentiation markers in A7r5 
cells. Cells were seeded at a low density (5,000 cells/well) and incubated for at least 
48 hours before switched to media containing either 5% or 0.5% FCS for a further 
72 hours. The samples were then probed with the appropriate primary and 
secondary antibody. Scale bar represents 50nm for all images. 
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Figure 4.13 Fluorescent immunocytochemical of SMC differentiation markers in 
A10 cells, SMA, CNN1 and SM-MHCII. Cells were seeded at a low density (5,000 
cells/well) and incubated for at least 48 hours before switched to media containing 
either 5% or 0.5% FCS for a further 72 hours. The samples were then probed with 
the appropriate primary and secondary antibody. Scale bar represents 50nm for all 
images. 
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Figure 4.14 SMA expression in rMSC, rSMC were used as a comparative for SMA 
expression. Cells were seeded at a low density (5,000 cells/well) and incubated for at 
least 48 hours before switched to media containing either 5% or 0.5% FCS for a 
further 72 hours. The samples were then probed with the appropriate primary and 
secondary antibody. Scale bar represents 50nm for all images. 
 
4.8.2 Relative gene expression analysis of A10 and A7r5 cell lines upon 
quiescence 
In order further investigate the MVSC marker expression in the A10 and A7r5 cell 
lines gene expression analysis was carried out using qRT-PCR. The analysis was 
completed by measuring the level of expression of both MVSC [Sox10, Sox17 and 
S100β] and SMC [SMA, CNN1, MHY1, MHY11, SMO] markers using real-time 
qRT-PCR. A10 and A7r5 cell lines were quiesced in low serum for 24h and then in 
parallel experiments serum deprived in 0.5% FCS for 72 hours or cells were 
supplemented with 5% FCS. GAPDH was used as a “house-keeping gene” for both 
assays. 
 The repercussions of serum deprivation on SMC differentiation and MVSC 
marker expression was evaluated by measuring the changes in expression of the 
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markers associated with each respective phenotype (as described above). In the A7r5 
cell line serum stimulation resulted in a significant increase in Sox10, Sox17 and 
S100β coupled with a decrease in SMC differentiation markers Sm1 and CNN1 
while expression levels of SMA and Sm2 increased. The greatest increase was found 
in S100β (Figure 4.15). In contrast the addition of serum to A10 increased SMC 
differentiation markers and the same increase was found in neural crest cell markers 
Sox10, Sox17 and S100β expression in these cells (Figure 4.15). 
 
Figure 4.15 qRT-PCR representative data for A10 and A7r5 cell lines after 
serum deprivation for 72h. Cells were seeded at 100,000 cells per well and were 
incubated until they reached confluency. mRNA was prepared as described in the 
methods section and data was analysed using the Comparative CT method (ΔΔCT), 
described by Livak and Schmittgen, 2001. 
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4.9 Differentiation Potential of A10 and A7r5 Cell lines 
The MVSC markers Sox10, Sox17 and S100β that are expressed in A10 and A7r5 
cell lines are associated with a stem cell like profile (Tang et al 2012). Their 
consistent expression in these embryonic vascular cell lines suggests that A10 and 
A7r5 cell lines may retain some stem cell like properties.  
To investigate the multipotent potential of A10 and A7r5 cell lines, they were 
treated with an induction media to stimulate adipocyte differentiation.  Adipocyte 
differentiation was measured using both classic Oil Red O staining and LipidTOXTM 
fluorescent staining after 14 d treatment with the induction media. Rat MSCs and 
rMVSCs were also treated with induction media and these populations served as a 
positive control (Figure 4.16). 
Figure 4.16 Adipocyte generation in A10 and A7r5 cell lines. Cells were seeded at 
low density (5,000 cells/well) and treated for 7-14 days with adipogenic induction 
media. The samples were then stained using Oil Red O dye/LipidTox fluorescent 
probe to visualise differentiated osteocytes. Scale bar represents 50nm for all 
images. 
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4.10 Adult Smooth Muscle cell cultures 
Since these embryonic cell lines displayed properties of multipotent cells it was 
hypothesized that adult smooth muscle cells in culture may still retain some of these 
properties. The cells in culture analysed previously in situ expressed high levels of 
Sox10. It is possible that the majority of cells initially isolated were Sox10 negative 
but that the Sox10 stem population out grew the negative responders. Protein 
analysis for of bovine, rat and murine smooth muscle cells was undertaken using 
western blot and FACS analysis. Representative differentiation markers were used to 
investigate the presence of both SMC [SM-MHCII, CNN1] and MVSC [Sox10, 
Sox17] markers. The presence of Sox10, Sox17 and S100β may indicate that smooth 
muscle cells in culture have been derived from a multipotent vascular stem cell. The 
fact that the smooth muscle cells present in situ in the vessel display low Sox10 
levels and high SM-MHCII levels reinforces this theory (Tang et al 2012, Kennedy 
et al 2014). 
Rat, bovine and mouse smooth muscle cells were analysed using 
immunoblotting. It was found that all three cell lines expressed SMC markers; SM-
MHCII and CNN1, and co-expressed MVSC markers; Sox10 and Sox17 (Figure 
4.17, 4.18). 
 
Figure 4.17 mSMC, rSMC, BaSMC protein immunoblot anlaysis for SMC markers 
SM-MHCII and CNN1. Cells were seeded at a density of 100,000 cells per well and 
left incubated for at least 48 hours before protein isolation was carried out. Samples 
were probed with appropriate primary and secondary antibodies and finally TMB 
for colorimetric analysis. 
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Figure 4.18 mSMC, rSMC, BaSMC protein immunoblot anlaysis for MVSC 
markers Sox10 and Sox17. Cells were seeded at a density of 100,000 cells per well 
and left incubated for at least 48 hours before protein isolation was carried out. 
Samples were probed with appropriate primary and secondary antibodies and 
finally TMB for colorimetric analysis. 
 
 
Figure 4.20 FACS analysis on mSMCs for SM-MHCII, CNN1 and Sox10. Cells were 
prepared as required for FACS analysis. Protein expression of the markers can be 
seen in red with secondary controls in black. The shift in peak indicated protein 
expression. 
 
Immunocytochemistry analysis of the expression of MVSC markers [Sox10, Sox17, 
S100β] in rat, murine and bovine smooth muscle was undertaken by other members 
of the lab as described in Kennedy et al. 2014. It was found that rSMCs and baSMCs 
expressed Sox10 by immunocytochemical methods. These results reaffirm the 
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results achieved in the study previously mentioned which was undertaken by 
collaborators of this project. All SMCs used for experiments were checked routinely 
for markers associated with their phenotype; SMA, CNN1 and SM-MHCII. 
 
4.11 Multipotent Potential of Smooth Muscle Cells 
The expression of these MVSC markers shows that the SMCs still retain some 
multipotent aspects. For this reason rSMCs were treated with osteogenesis induction 
media. rMSCs were used as positive controls (Figure 4.21). The results indicate that 
rSMCs have lost their potential to differentiate to osteocytes. The trilineage 
differentiation capabilities of cells is associated with MSCs, this means that although 
the rSMCs express phenotypic stem cell like markers they have less mulipotency 
potential than MSCs have. 
 
Figure 4.21 Osteogenesis differentiation of MSC and rSMC. Cells were seeded at 
low density (5,000 cells/well) and treated for 21 days with osteogenic induction 
media. The samples were then stained using Alizarin Red dye to visualise 
differentiated osteocytes.  
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4.12 Local expression of Stem associated markers C-Kit and CD133  
C-kit (CD117) is a stem cell growth factor receptor associated with the hematopoetic 
system as previously described (Fazel et al. 2006). The expression of c-Kit was 
analysed using immunocytochemistry and FACS. Both A7r5 and A10 cells 
expressed c-Kit (Figure 4.22). MVSC and SMC cells were also screened and the two 
lines also displayed c-Kit positivity by both protein detection methods (Figure 4.23, 
4.24). CD133 is associated with hematopoetic cells and is thought to be involved 
with angiogenesis. All three cell lines A10, A7r5 and MVSC expressed CD133 
(Figure 4.25). This might indicate that these cells could play a role in angiogenesis 
during embryonic development or post natal injury.  
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Figure 4.22 c-Kit expression in A10, A7r5, MVSC and rSMC cells. Cells were 
seeded at a low density (5,000 cells/well) and incubated for at least 48 hours before 
probing with the appropriate primary and secondary antibody. Scale bar represents 
50nm for all images. 
 
 
Figure 4.24 FACS analysis of c-Kit on A7r5, A10 and MVSC cells. Cells were 
prepared as required for FACS analysis. Protein expression of the markers can be 
seen in red with secondary controls in black. The shift in peak indicated protein 
expression. 
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Figure 4.25 FACS analysis of CD133 on A7r5, A10 and MVSC cells. Cells were 
prepared as required for FACS analysis. Protein expression of the markers can be 
seen in red with secondary controls in black. The shift in peak indicated protein 
expression. 
 
4.13 Local expression of Flt-1/Vascular Endothelial Growth Factor Receptor 
Flt-1 or Vascular Endothelial Growth Factor (VEGF) receptor has been shown to 
influence vascular smooth muscle cell functions (Orlandi & Bennett 2010). A10, 
A7r5 and MVSC were analysed for the presence of Flt-1 using FACS analysis. Flt-
1expression has been found in atherosclerotic lesions, therefore it was of great 
interest to see the protein analysis of this marker in the cell lines in culture. It was 
found that all three cell lines were positive for VEGF receptor (Figure 4.26). 
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Figure 4.26 FACS analysis of Flt-1 expression in A7r5, A10 and MVSC cell lines. 
Cells were prepared as required for FACS analysis. Protein expression of the 
markers can be seen in red with secondary controls in black. The shift in peak 
indicated protein expression. 
 
4.14 Growth Profile of MVSC, A10 and A7r5 Cell lines 
A proliferation Assay was carried out on MVSCs, A10, A7r5 and rSMC cell lines. 
This was to compared their growth rate over time. Cells were seeded at equal density 
to begin with and analysis of the samples was carried out for 12 days. The samples 
were DAPI stained on days 1, 3, 5, 7, 9 and 12 (Figure 4.27). It was found that A10 
and A7r5 had similar growth patterns. After day 8 A7r5 proliferation plateaued but 
A10 cells continued to grow. MVSCs lagged behind initially and A10 and A7r5 cells 
had a faster growth rate, however, MVSCs recovered after day 12. 
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Figure 4.27 Proliferation assay for A10, A7r5 and MVSC cells. Cells were seeded at 
low equal seeding density (10,000 cells/well). Multiple samples for each cell line 
were prepared. Cells were fixed in formaldehyde after 1, 3, 5, 7, 9 and 12 days and 
stained with DAPI to visualise the nuclei and allow for counting. 
  
4.15 Summary 
• Rat embryonic smooth muscle cell lines A10 and A7r5 were analysed for the 
presence of stem cell like markers expressed in MVSCs [Sox10, Sox17, 
S100β]. Protein analysis was carried out using immunocytochemistry, 
western blotting and FACS analysis. Both cell lines were positive for the 
neural stem cell markers. 
• In parallel experiments the cell lines were analysed for their SMC marker 
expression, both found to be SMA+/CNN1+/SM-MHCII+, with A7r5 cells 
displaying reduced level of myosin in comparison with A10 cells. 
• A10 and A7r5 cell lines were quiesced for 48h and then either serum 
deprived for a further 72h in 0.5% FCS or supplemented with media 
containing 5% FCS. The effects of serum were investigated using 
immunocytochemistry. 
• It was found that the serum deprivation of A7r5 and A10 cells made the cells 
more smooth muscle cell like, with an increase in actin filaments observed in 
both cell lines. Calponin filaments were clearer upon serum deprivation with 
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an overall increase in intensity for both cell lines. There was no apparent 
change in myosin expression. 
• Rat MSCs were used as a comparison for SMA. Serum deprivation in the 
MSCs caused an increase in the actin filaments and staining pattern was 
similar to that of actin in SMCs. 
• qRT-PCR analysis was used to analyse the gene expression of the effects of 
serum. In A7r5 cells, serum stimulation caused an increase in Sox10, Sox17 
and S100β coupled with a decrease in SMC differentiation markers Sm1 and 
CNN1 while expression levels of SMA and Sm2 increased. In contrast, 
serum increased all the expression of all genes in A10 cells. 
• A10 and A7r5 cells both showed potential to differentiate into adipocytes. 
• Adult smooth muscle cells were examined for stem cell markers by western 
blot. Rat, murine and bovine SMCs all expressed Sox10, Sox17 and S100β at 
a protein level. 
• Rat SMCs did not retain potential to differentiate down the osteocyte lineage. 
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Chapter 5:  
NE4C as a model for Multipotent 
Vascular Stem Cells 
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5.0 Introduction 
Another aim of this project was to identify a cell line that could be used routinely in 
experiments as a representative for the MVSC cell line (with subsequent 
confirmation of results using the MVSC cells). MVSCs are difficult to isolate and 
lose multipotency as they are passaged. This would mean a lot of labour to use this 
cell line continuously. The NE4C cells are an immortalised neuroectodermal cell 
line. It was proposed that these cells could mimic MVSCs for future experiments. 
Neural stem cells develop from the neural crest, which is derived from the ectoderm. 
MVSCs were isolated from the aortic arch which is also of ectoderm origin (Tang et 
al 2012). For this reaon the NE4C cell lines were chosen as the representative cell 
line. These cells are characterised by their high levels of Nestin. Neural crest stem 
cells have also been shown to express Pax6 (Xie et al. 2011b). 
For the purpose of this work the NE4C cells were characterised for NCSC markers 
[Nestin, Pax6] and MVSC associated markers [Sox10, Sox17, S100β] in order to 
establish how similar these cells were to the isolated MVSC population previously 
described. Their capability to differentiate to osteocytes and adipocytes was 
investigated using lineage induction media. In order for these cells to be used as 
SMC progenitors it is essential that they can differentiate to SMCs after treatment 
with TGFβ1. The cells were treated as MVSCs were and it was found that the cells 
did show increased myosin expression immunocytochemically. However, these 
experiments are preliminary and further investigations need to be undertaken to 
confirm what was found here. 
 
5.1     Materials and Methods 
All materials used were of the highest purity available commercially. Cell culture 
was carried out as described in Chapter 2. NE4C cells used are a commercially 
available neuroectodermal stem cell line. The cells were treated using TGFβ1 and 
PDGFBB for smooth muscle cell differentiation as previously described. Protein 
analysis was carried out using FACS, western blotting, immunocytochemistry and 
confocal imaging. The cells were treated with induction media for adipogenic and 
osteogenic differentiation as previously described.  
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5.2  Results 
5.3 Cell lines and Reagents 
NE4C cells are a murine neuroectodermal cell line. The cell line was established 
from primary brain cultures which were prepared from the fore and midbrain 
vesicles of 9-day-old mouse embryos lacking the functional p53 genes. These cells 
have the capability to divide continuously if they are maintained under correct 
culture conditions. According to the depositary these cells display many 
characteristics of neural stem cells, such as nestin and SSEA1 immuno reactivity, 
self-renewal and differentiation into distinct neural cell types upon appropriate 
induction. 
 
5.4 Expression profile of neural stem cell markers 
To verify that these cells express markers associated with the neural crest, the cell 
line was screened with antibodies against Nestin and Pax6. Immunocytochemistry 
and FACS were used to analyse protein expression of the two markers. The cell line 
expressed both stem markers, this allowed for further analysis to be carried out on 
the NE4C cell line (Figure 5.0. 5.1). 
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Figure 5.0 Immunocytochemical data for Nestin and Pax6 on NE4C cells. Cells 
were seeded at a low density (5,000 cells/well) and incubated for at least 48 hours 
before probing with the appropriate primary and secondary antibody. Scale bar 
indicates 50nm for all images 
. 
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Figure 5.1 FACS data for Nestin and Pax6 on NE4C cells. Cells were prepared as 
required for FACS analysis. Protein expression of the markers can be seen in red 
with secondary controls in black. The shift in peak indicated protein expression. 
 
 
5.5 NE4C expression of MVSC associated neural and glial stem cell markers 
MVSCs isolated were taken from the aortic arch which is also of neuroectodermal 
origin. For this reason it was hypothesized that NE4Cs could be used as a model for 
the MVSCs. In order for these cells to be used as an MVSC-like cell, the properties 
of the cell line had to be examined. This included expression of the stem cell markers 
Sox10, Sox17 and S100β. NE4Cs were found to be positive for the three MVSC 
markers using both immunocytochemistry and FACS analysis (Figure 5.2, 5.3). 
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Figure 5.2 Representative data for Sox10, Sox17 and S100β expression in NE4C 
cells. Cells were seeded at a low density (5,000 cells/well) and incubated for at least 
48 hours before probing with the appropriate primary and secondary antibody. 
Scale bar indicates 50nm for all images. 
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Figure 5.3 FACS data for Sox10, Sox17 and S100β expression in NE4C cells. Cells 
were prepared as required for FACS analysis. Protein expression of the markers can 
be seen in red with secondary controls in black. The shift in peak indicated protein 
expression. 
 
5.6 Multipotent potential of NE4C cells 
5.7 NE4C differentiation to SMC  
MVSCs showed a good response to TGFβ1 activation for SMC differentiation. It 
was hypothesized that the NE4C cell line would respond in a similar manner to the 
stimuli. The NE4C cells were treated in the same manner as the MVSCs were, they 
were treated with an SMC induction media composed of 5% FBS, supplemented 
with 5ng/ml of TGFβ1 and 10ng/ml PGGFBB. The cells were tested for the presence 
of SMA, CNN1 and SM-MHCII proteins using immunocytochemistry (Figure 5.4). 
The cells expressed levels of SMA and CNN1 before administration of the induction 
media. After the 72 hour treatment there was no noteable increase in SMA 
expression with no filaments visible. CNN1 expression seemed to increase slightly 
with regard to fluorescent intensity. The cells were SM-MHCII- in maintenance 
media and after treatment an increase in expression was observed but there was no 
strong visibility of filaments. Lysates for NE4C cells were prepared +/- TGFβ1 
treatment. Samples were probed for CNN1 and SM-MHCII (Figure 5.5). There was 
an increase in both expression markers after treatment. 
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Figure 5.4 Representative immunocytochemistry data for SMC markers SMA, 
CNN1, SM-MHCII on NE4C cells in maintenance media or after treatment with 
5ng/ml of TGFβ1 and 10ng/ml PGGFBB for 5 days. The cells were then probed with 
the appropriate primary and secondary antibody. Scale bar indicates 50nm for all 
images. 
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A             
Figure 5.5 CNN1 and SM-MHCII expression in lysates from NE4C cells. Cells 
were seeded at a density of 100,000 cells per well and left incubated for at least 48 
hours before protein isolation was carried out. Samples were probed with 
appropriate primary and secondary antibodies and finally TMB for colorimetric 
analysis. 
 
5.7.1 Role of Smad2/3 in the induction of SMC differentiation from NE4C 
cells 
The response of TGFβ treatment was not as great as expected and due to the fact that 
the cells seemed to express some levels of SMA and CNN1 prior to treatment. 
Therefore, another method of analysis was required. As previously described the 
TGFβ pathway is Smad2/3 dependent. Hence, before any further analysis was 
B 
C 
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undertaken it was investigated whether or not the NE4C cells have the TGFβ1 
receptor 
The activation of Smad2/3 with TGFβ1 would cause a marked increase 
expression in phosphoSmad2/3. The expression increase in phosphoSmad2/3 would 
indicate the presence of the TGFβ1 receptor on the cell surface. Western blot 
analysis was used to determine if the receptor was present. NE4Cs were treated as 
previously described (+/- TGFβ). Whole cell lysates were used for the detection. 
Smad3 was used as an internal loading control (Figure 5.6A). PhosphoSmad2/3 was 
not detected in either maintenance or treated samples (Figure 5.6B). This result 
indicates that the TGFβ1 pathway was activated (as suggested with ICC data) and is 
working independently of Smad2/3. 
 
 
 
 
 
 
 
 
 
 
 
A 
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B 
 
Figure 5.6 Smad3 and phoshoSmad3 expression in cell lysates after treatment with 
TGFβ1. Cells were seeded at a density of 100,000 cells per well and left incubated 
for at least 48 hours before protein isolation was carried out. Samples were probed 
with appropriate primary and secondary antibodies and finally TMB for 
colorimetric analysis. 
 
5.8 Adipocyte and Osteocyte differentiation 
In order for a cell type to be referred to as multipotent with respect to a mesencymal 
stem cell, it must be capable of differentiation to osteocytes, chondrocytes and 
adipocytes. For the purpose of these experiments two lineages were chosen to 
investigate the potential of the NE4C cells; Osteocyte and Adipocyte (Figure 5.7, 
5.8). Cells were treated in parallel experiments with appropriate induction media and 
left to undergo differentiation for the specific times required for each lineage. Rat 
MSCs were used as positive controls for both experiments. NE4Cs were capable of 
differentiating to an osteocyte. 
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Figure 5.7 NE4Cs differentiate into osteocytes, images were taken at phase contrast 
using low power (10X) and high power (40X) magnifications. Cells were seeded at 
low density (10,000 cells/well) and treated for 21 days with osteogenic induction 
media. The samples were then stained using Alizarin Red dye to visualise 
differentiated osteocytes. Scale bar indicates 50nm for all images. 
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Figure 5.8 NE4Cs differentiate into adipocytes, images were taken at phase contrast 
using low power (10X) and high power (40X) magnifications. Cells were seeded at 
low density (10,000 cells/well) and treated for 7-14 days with adipogenic induction 
media. The samples were then stained using Oil Red O dye fluorescent probe to 
visualise differentiated osteocytes. Scale bar indicates 50nm for all images. 
 
5.9 Summary  
• NE4C cells express neural stem cell markers Pax6 and Nestin. 
• The cells also express markers associated with the MVSC cell line: Sox10, 
Sox17, S100β 
• The cells were capable of differentiation into both osteocytes and adipocytes, 
demonstrating that they have the multipotent properties that are associated 
with MSCs and MVSCs 
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• NE4C cells showed slight potential for differentiation into SMCs using 
TGFβ1, with a flourescent increase in SM-MHCII found after treatment. 
• The TGFβ1 pathway, appears to be acting SMAD2/3 independent as there 
was no phosphoSMAD detected in TGFβ1 treated samples 
• Further analysis is needed to confirm these results regarding TGFβ1 
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Chapter 6: 
Discussion 
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6.0 Discussion 
6.1 Multipotent Vascular Stem Cell Isolation and Characterisation 
Cardiovascular disease is one of the world’s biggest threats to mortality at the 
moment. There are many contributing factors that have caused the increase in death 
rates associated with this disease. Ireland in particular has a huge rate death 
associated with this disease with 38% of annual deaths connected to CVD. With new 
age diets introducing food with high fat content, the fast paced lifestyles that we lead 
and the huge focus on social side of life there is a real need to address the issue of 
CVD. There are many types of CVD including stroke, aortic disease, coronary heart 
disease and peripheral artery disease to name a few. The main focus of this project is 
on blockages in the main arteries associated with the heart, mainly put down to 
atherosclerosis. As previously discussed stent implantation is used to combat the 
blockage and to reduce its size allowing blood to pass freely. However, stent failure 
rate is high and other side effects can occur as a result of this (Nikolsky et al. 2003). 
The failure of these stents has been associated in part with the infiltration of cells 
into the lesion (Chaabane et al. 2013). It was originally hypothesised that the cells 
involved were smooth muscle cells that had dedifferentiated, but it is now thought 
that the cells involved are resident stem cells that differentiate into SMCs, bringing 
about the question, is cardiovascular disease is a stem cell disease? 
 The stem cell origin of vSMCs within vascular lesions has been very 
controversial in more recent years (Schober & Weber 2011); (Torsney & Xu 2011; 
Fukuda & Aikawa 2010b; Orlandi & Bennett 2010; Tang et al. 2012; Bochaton-
Piallat et al. 1996). Initial studies were carried out in studies using canine carotid 
arteries by Holifield et al. (1996). In this study, proliferative SMCs were found in the 
neointimal and it is suggested that these modulated cells were not derived from 
differentiated SMCs but are sourced from a medial SMC that is myosin type 2 
negative (SM-MHCII). 
The original “de-differentiation” of SMC theory has been questioned and 
more recently this phenomenon has been attributed to stem cells (Nguyen et al 2013, 
Tang et al 2012, Klein et al 2011). Recent studies undertaken by Tang et al 2012 
show data that conflicts with the original theory that smooth muscle cells are not 
terminally differentiated. Nguyen et al 2012 argue that strong evidence exists 
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showing that smooth muscle cell plasticity exists and that SMCs are capable of 
undergoing phenoptyic transition from a contractile state to a less differentiated 
synthetic state. They also focus on how this process is thought to underlie some 
vascular occlusive diseases. Nemenoff et al 2011 show evidence that differentiated 
SMCs can undergo phenotypic modulation and contribute to vascular remodelling 
using tamoxifen inducible SM MHC-Cre T2/Rosa26-floxStop/βGal mice, which 
directly contradicts the findings by Tang et al 2012 (Nguyen et al 2012). Tang et al 
have argued that it is likely that many of the historic experiments which have been 
carried out demonstrating SMC plasticity in primary cultures, were carried out cells 
that were assumed to be derived from SMCs. They highlight the fact that the 
possibility of a multipotent cell was never considered for these experiments and that 
previous research should be re-evaluated taking these resident vascular progenitor 
cells into considerations. Both groups highly emphasize the need for a strong lineage 
tracing mechanism in order to conclude the origin of the SMC involved with this 
type of vascular disease (Tang et al 2012, Nemenoff et al 2012). 
Since primarty studies, many types of SMC-related progenitor cells have 
been identified within the tunica media. The cells identified are mainly 
mesenchymal-like cells displaying some of the multipotent properties of these cells 
such as adipocyte and/or osteocyte differentiation. Others have identified progenitor 
cells in the adventitial layer that express Sca-1+ and are capable of SMC 
differentiation (Sainz et al. 2006). These cells with Sca-1+ expression were also 
found to contribute to atherosclerosis of vein grafts in ApoE-deficient mice (Hu et al. 
2004; Xu 2008). The three main types mentioned in the literature include resident 
vascular stem cells, circulating progenitors and bone marrow derived stem cells. 
(Tanaka et al. 2003) used a murine model with GFP tagged bone marrow cells. After 
wire injury, GFP tagged cells were found in the intima. (Werner 2002) also reach the 
same conclusion that vascular lesion damage can be initiated by bone marrow 
derived cells. In a conflicting study (Hu 2002) provide evidence that the SMCs 
involved in transplant atherosclerotic lesions are cells which have been derived from 
the recipient and not from the bone marrow. Another study carried out by (Simper 
2002) identified a population of circulating smooth muscle progenitor cells in blood, 
the research suggests that there is a possibility that circulating progenitor cells were 
involved in vascular remodelling. 
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The cell population of interest here is the “resident” stem cell population. Tang et al 
2012 have identified a population of MVSCs that are capable of differentiation in 
vivo and in vitro into SMCs. One of the aims of this study was to isolate an MVSC 
population from rat aortic medial tissue. Resident MVSCs were successfully 
isolated. Once isolated the objective was to fully characterise these cells and to 
examine them for stem cell like properties, differentiated smooth muscle cell 
markers and to evaluate their phenotype with respect to mesenchymal stem cell 
features. An exact profile of MVSC marker expression has not been elucidated, 
partly due to the differences in the mechanism of how the cells are obtained and 
subsequently cultured, slight differences in media composition and sub culturing 
techniques could contribute to this. The heterogeneity of the resident cells is also due 
to fact that cells can easily gain or lose marker expression in vivo and in vitro, for 
example SMCs are known for losing their myosin expression in culture. Stem cells 
are extremely sensitive and this can cause high variability from lab to lab. 
 MVSCs were generated using an explant method from the medial layer of 
aortas retrieved from Sprague Dawley rats. They were the first few cells to migrate 
off the explant tissue. The appearance of MVSCs under phase contrast differs to that 
of regular SMCs. MVSCs grow into a star like pattern when they are confluent in 
comparison with the spindle, elongated shape associated with the smooth muscle 
cell. Immediately it was clear that the MVSC population isolated was different to 
regular smooth muscle cells. 
 Upon isolation MVSCs were successfully characterised for three different 
subset panels of markers associated with neural/astrocyte cells (Sox10, Sox17, 
S100β), mesenchymal stem cells (CD29, CD44, CD146) and smooth muscle cells 
(SMA, CNN1, SM-MHCII). The three collections of markers were chosen in 
keeping with the theory that MVSCs differentiate to MSCs which in turn 
differentiate to SMCs, which infiltrate over time after administration of the stent 
within the aorta. Protein analysis using immunocytochemistry, FACS and western 
blotting showed that the MVSCs were positive for Sox10, Sox17 and S100β. These 
results are similar to what Tang et al. discovered in 2012. The cells were also 
positive for SMA and CNN1. Only SM-1 was detected in MVSCs lysates, no SM-
MHCII was presented, this result coincides with studies undertaken by Tang et al. in 
2012. FACS analysis showed fluorescence when the SM-MHCII antibody was used. 
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Immunocytochemistry showed that the cells were negative for the antigen as there 
were no filaments present which is the indicator of mature SMCs. The slight stain 
found was attributed to background staining. As FACS analyses a much greater 
population of cells, the fluorescence detected showing “expression” was also 
attributed to the non specific binding of the primary antibody. This was confirmed 
by western blot whereby the SM-MHCII antibody detected both myosin SM-MHCI 
and SM-MHCII isoforms. Tang et al. who isolated MVSCs in the same manner 
using different arteries describe their MVSC population to be Sox10+/SM-MHCII-. 
Studies shown here by this group and also by other members of the team in 
Rochester University have shown that the Sox10 expression in vivo is very low 
(Figure 6.0), with only a small percentage of cells expressing the marker (10% in the 
case of Wang et. al). Collaborative researchers at the University of Rochester have 
shown using lysates from the medial layer to express low levels of Sox10 and high 
levels of SM-MHCII, which is in keeping with the theory that Sox10 levels in vivo 
are low (Kennedy et al. 2014). 
 
 
 
Figure 6.0 Sox10 expression is low in the vessel and SM-MHCII expression is high. 
A small minority expressing Sox10+/SM-MHCII- exists in the vessel wall. This was 
confirmed by in situ analysis (Wang et al 2012) and from cell lysates isolated by 
collaborators in Rochester. 
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As previously described, a huge controversy exists between different scientist 
with regard to the origin of SMCs found in neointimal lesions, whether they are 
derived from resident progenitors, resident mature SMCs or both. However, there is 
no controversy surrounding the phenotype and characteristics of medial SMCs in 
normal vessels in situ before culture. Tang et al 2012 describe how they prepare 
SMCs from explant culture whereby SM-MHCII was tagged to green fluorescent 
protein (GFP). The resulting culture was a population on SMCs that were 
immunocytochemically GFP negative (therefore SM-MHCII negative) but expressed 
Sox10, Sox17 and S100β. However, the cells acquired SM-MHCII when sub-
cultured in vitro or activated by Notch stimulation ligand or by induction using 
TGFβ1. In contrast medial cells in vitro prior to enzymatic dispersal are mainly GFP 
positive and the expression of Sox10, Sox17, S100β is minimal to none. The profile 
of SM-MHII+/Sox10- is maintained when the cells are enzymatically dispersed and 
probed in culture at P0. They also demonstrate how the injured vessel is populated 
mainly with Sox10+/SM-MHCII- cell type in comparison with a healthy vessel. This 
data indicates that the cells re-populating the injured vessel are from an MVSC 
origin (Figure 6.1) (Tang et al. 2013).  
 
 
Figure 6.1 Majority of the cell phenotype changes after vessel injury/diseased state 
from a Sox10-/SM-MHCII+ to Sox10+/SM-MHCII- 
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For the purpose of this research, the phenotype of the majority cells in the 
tunica media (without stem-like properties) of the aorta was investigated. The medial 
layer of the aorta was enzymatically dispersed in an enzyme cocktail. These cells 
were seeded at a low passage upon isolation and analysed immunocytochemically 
for Sox10 and SM-MHCII. It was found that these cells all expressed SM-MHCII, 
with clear visibility of myosin filaments. There was very little Sox10 expression, 
some Sox10 was found to be expressed in the cytoplasm but none in the nucleus. 
The research undertaken by (Rehberg et al. 2002) suggests that Sox10 is an active 
nucleocytoplasmic shuttle protein, these findings can explain the cellular localisation 
of the staining in the immunocytochemical analysis. In a parallel experiment MVSCs 
were seeded at low passage after isolation and as before the cells all displayed Sox10 
positivity with no expression of SMC marker SM-MHCII. These studies are similar 
to what Tang et. al 2012 discovered. 
 An aim of this study was to define MVSC transition to SMC following 
treatment with media containing serum and in a parallel experiment to examine their 
transition following treatment with TGFβ1 and PDGF-BB. MVSCs isolated here 
were similar to that of Tang et al 2012 whereby when the cells were grown in 
maintenance media they were SM-MHCII- but were positive for SM-MHCI, Sox10, 
Sox17 and S100β. However as the cells were cultured in 10% FBS the results were 
different. It was found that the expression of Sox10 persisted after culture in 10% 
FBS for 21 days. Although the expression of SMC differentiation marker SM-
MHCII in particular was enhanced when the MVSCs were grown in non-
maintenance media (ie differentiation media) an even greater increase in expression 
was found following stimulation with a differentiation media supplemented with 
TGFβ1 and PDGF-BB with clear visibility of filaments. MSCs have been shown to 
differentiate to SMCs with TGFβ1 stimulation, mediated by notch signalling 
(Kurpinski et al. 2010). TGFβ1 expression has been shown to be elevated in human 
vascular restenosis lesions (Nikol et al. 1992). The study shows that TGFβ1 plays an 
important role in the remodelling of the vasculature after injury, it is possible that 
one of these roles includes stimulating MVSCs to migrate from the medial layer to 
the intima disguised as newly differentiated SMCs with their newly acquired myosin 
expression. Furthermore, TGFβ1 inhibition has also been found to prevent injury 
induced lumen reduction instead, promoting vessel enlargement (Ryan et al. n.d.). In 
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contrast to Tang et al 2012, MVSCs isolated in this study were Sca-1+, this suggests 
that Sca-1+ may persist in cells other than the adventitial. Tang et al screened their 
MVSC population in differentiation media, whereas this population were Sca-1+ in 
maintenance media. When the MVSCs form this study were grown in differentiation 
media and screened they too were negative which coincides with Tang et al 2012. In 
a similar manner NE4C in neural stem cell media are Sca-1+ but when grown in 
differentiation media they are Sca-1-. There may well be a relationship between 
progenitors in the media and in the adventitia but the depth of this relationship is 
unknown. The presence of Sca1 in the MVSCs suggests an adventitial origin for 
these cells. There could well be a cross over at the adventitial/medial boundary 
whereby the cells display a similar phenotype. The presence of Sca1 could also 
indicate that some of the adventitial cells remained on the medial layer within this 
boundary after the removal of the adventitial layer. 
It was important to analyse mesenchymal markers to see if the MVSC 
population represented any of the intermediate mesenchymal populations. Since 
MVSCs expressed markers associated with smooth muscle cells it was highly likely 
that they could express some MSC markers. Similarly a rat MSC cell line was 
screened for the presence of stem cell markers associated with the MVSC to 
investigate if properties associated with these markers are retained. It was found that 
MVSCs expressed CD29, CD44 but not CD146. In comparison MSCs co-expressed 
Sox10, Sox17, S100β, CD29, CD44 and CD146. MSCs showed slight expression of 
SM-MHCII and still retained SMA and CNN1 markers as the move closer to the 
SMC phenotype and become less multipotent (Liu et al. 2013). There was some 
expression cross over between the two cell lines, indicated in Figure 6.2. Klein et al 
2011 isolated a population of resident vascular stem cells that expressed CD44 with 
the ability to differentiate into SMCs and also contribute to new vessel maturation.  
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Figure 6.2 Overlap of expression markers between MSCs and MVSCs 
 
MSC- like cells described by (Tintut et al. 2003) express CD29 and CD44 
similar to what was found in the MVSC population isolated in this study. Tintut et al 
found that the population they isolated from the artery wall was capable of 
differentiation into chondrocytes and adipocytes but not osteocytes. In contrast when 
MVSCs were stimulated with appropriate induction media they had the potential to 
differentiate into osteocytes and similarly, MSCs in culture up to passage 28 retained 
the potential to differentiate into both adipocytes and osteocytes. In another study 
(Crisan et al. 2008), identified a population of perivascular MSC-like cells that were 
CD146+ and still retained the potential to differentiate to osteocytes, chondrocytes 
and adipocytes. 
These cells are thought to become ‘modulated’ regarding their SMC 
phenotype, with a decrease in SMC differentiation markers as the cells are passaged 
over time. In particular SM-MHCII is down regulated in comparison with freshly 
isolated P0 cultures or cells analysed in situ. It is difficult to pin point the exact 
reason as to why the loss of SM-MHCII occurs if it is not attributed to the fact the 
cells are stem cells and never expressed myosin to begin with. However, as 
discussed before it may be due to the de-differentiation of SMCs to a synthetic 
phenotype, but SMCs are also known for losing SMC differentiation markers over 
time in culture. The loss could also be due to an environmental factor if the cells are 
not getting the cytokines in vitro that they would be stimulated by in vivo. Studies 
from the 1970’s and 1980’s focus particularly on the loss of SM-MHCII in culture 
(American et al. 1979). Other forms of myosin exist and they are not fully 
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understood, this makes it hard to distinguish exactly what myosin is being expressed 
by cells and this can cause difficulties for interpretation of results, and conflicting 
results (Rovner et al. 1986). Antibody variation and specificity from lab to lab can 
also result in conflicting data. 
  
6.2  Evaluation of Stem Cell markers in Embryonic and Adult SMC lines 
The way in which vSMCs behave in culture has long been a subject for investigation 
(Sainz et al. 2006). In culture, SMCs isolated from different parts of vessels display 
heterogeneity with respect to what markers they express (Orlandi et al. 1994). The 
idea that these SMCs in culture have arisen from stem cells opens up questions about 
the phenotype and origin of the SMCs cells in vivo that are involved in neointimal 
infiltration (Tang et al. 2013; Orlandi & Bennett 2010); Stoneman 2011). Originally 
these cells were thought to be modulated “de-differentiated” SMCs that had reverted 
back to a synthetic state, but more recently the idea that these cells in vivo and in 
vitro originate from stem cells is the subject of debate. For the purpose of this study 
A10, A7r5 and smooth muscle cell lines derived from rat, murine, bovine were 
analysed for SMC and MVSC differentiation makers, growth properties and the 
multipotency capabilities of the cell lines were assessed.  
 Both embryonic cell lines A10 and A7r5 and adult aortic SMCs have been 
shown by researchers to express a panel of well recognised SMC differentiation 
markers including SMA, CNN1, SM22 and tropoelastin. Although SM-MHCII is the 
most specific marker to SMCs the expression of this late stage markers is less 
common in these cultures (Manabe & Owens 2001; Firulli et al. 1998; Bochaton-
Piallat et al. 1992). Bochaton-Piallat ML et al 1996 induced intimal thickening (IT) 
by endothelial injury and subsequently cultured two cell populations from the intimal 
layer. Two distinct populations were noted, with epithelioid cells dominating the IT 
and spindle shaped cells more frequent in the media. These epithelioid “pup” cells 
resembled the phenotype of A10 cells and to some extent A7r5. A10 and A7r5 cells 
were also similar to new born rat SMCs as they continued to express SMA and SM-
MHCII when cultured over time (Bochaton-Piallat et al. 1992). Both A10 and A7r5 
cell lines expressed SMC markers SMA and CNN1, the two cell lines had similar 
growth patterns regarding these two markers (D. C. Graves & Yablonka-Reuveni 
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2000). When both cell lines were serum deprived the expression intensity profile of 
SMA and CNN1 increased with noteable enhanced filaments. This increase in 
contractile protein expression has been noted in other studies (Li et al. 1999). In 
comparison the expression of SM-MHCII in A10 and A7r5 cells not uniform and the 
pattern of the expression marker differed (Firulli et al. 1998). A10 cells expressed 
mainly Sm2 with some level of myofilaments visible under serum and serum 
deprived conditions. In contrast to A10, A7r5 cells expressed little or no filaments, 
the staining was attributed to non-muscle SM-MHCII. These cells do however still 
share several characteristics with neointimal cells including actin and non-muscle 
SM-MHCII expression (Rao et al. 1997). 
 As previously discussed the origin of cells present in neointimal cells is still 
unknown and research continues in this area. Since A10 and A7r5 cell lines represent 
embryonic SMCs this prompted the investigation of the origin of these cells and their 
expression of markers associated with MVSCs. The expression of these markers in 
adult SMC lines was of great interest to see if these cells retained any of the makers 
associated with MVSCs while co-expressing relevant SMC markers. 
Lineage tracing has been used to try resolve whether adult rat SMCs are 
derived from differentiated mature SMCs from the medial layer (Nemenoff et al. 
2011) or from a stem cell population (MVSCs) (Tang et al 2012). Nemenoff et al. 
2011 labelled bone marrow cells and showed that they were not involved with 
neointimal formation but that the cells accumulating in the lesion were resident 
SMCs. On the other hand, Tang et al showed that resident multipotent vascular stem 
cells differentiated to SMCs and infiltrated the neointima and that these particular 
cells were responsible for vascular remodelling – not resident SMCs that had 
dedifferentiated. SM-MHCII expression plays a large role in understanding what 
cells are involved in restenosis. Is it the resident MVSCs that are originally myosin 
negative that infiltrate or is it that a smooth muscle cell can become synthetic and 
lose its myosin expression? Epigenetic studies have been under taken to track the 
histone modifications of the MHY11 locus in vivo and in vitro. These studies back 
up the research of other groups that suggest SMCs in culture and SMCs involved in 
vascular remodelling are derived from mature vessel resident SMCs (Gomez et al. 
2013) (Gomez & Owens, 2012). When studying loss or gain of marker expression or 
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change in cell phenotype, epigenetic studies are very useful but in the case of these 
embryonic cell lines they express both panels of MVSC and SMC markers. 
Recent studies from (Ciceri et al. 2012; Liao et al. 2013) have suggested that 
rSMCs in vitro under specific conditions can differentiate to osteogenic and skeletal 
muscle lineages. This supports the theory that SMCs in culture retain stemness and 
demonstrate plasticity by acquiring neural cell markers. Similarly somatic cells have 
been shown to respond to stimulus-triggered acquisition of pluripotency (Obokata, 
Wakayama, et al. 2014; Obokata, Sasai, et al. 2014). 
It is possible that SMC cells in culture (eg A10, A7r5) that express 
multipotent markers are in fact de-differentiated SMCs that have been derived from 
differentiated smooth muscle cells. If this were the case it would mean these cells 
have the capability to revert back to a multipotent/pluripotent state when subjected to 
certain factors and begin to express stem cell like markers such as the neural crest 
markers observed in A10, A7r5 and adult SMC cell lines. This study demonstrates 
that both A10 and A7r5 cells co-express MVSC markers [Sox10, Sox17, S100β] 
(Tang et al. 2012), SMC markers [SMA, CNN1, SM-MHCII] and also express stem 
cell antigen 1 which is associated with multipotent progenitor cells (Holmes & 
Stanford 2007) and resident adventitial progenitor cells (Wu et al. 2014). A10 and 
A7r5 cell lines still retain some of the differentiation capabilities associated with 
multipotent cells. With appropriate induction the cells differentiated to adipocytes in 
the same manner as MSCs and MVSCs did. Although there was a smaller percentage 
of differentiation in A10 and A7r5 cells in comparison with MSCs/MVSCs, the 
adipocyte formation was still evident. An experiment was carried out by a member 
of the lab group using DAPT. DAPT, which inhibits Notch signalling and is 
fundamental for MSC to SMC differentiation (Doi et al. 2009). The result achieved 
suggests that DAPT significantly altered both MVSC and SMC differentiation 
markers in A10 and A7r5 cells promoting neural stem cell phenotypes while 
increasing differentiation. Notch has previously been shown to promote de-
differentiation of SMCs (Morrow et al 2005).  
The reasoning behind why MVSC neural stem cell markers are expressed in 
SMC lines in culture is unknown. It is possible that SMC lines in culture originate 
from MVSCs and that after time in culture SMCs differentiate from these and out-
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grow the de-differentiated SMCs and over time they dominate the culture (Tang et al 
2012). Proliferation assays were carried out on MVSCs, A10 and A7r5 cell lines to 
compare their growth rates. The results suggest that MVSCs take longer to recover 
initially after being seeded. They lag behind the two embryonic cell lines in the early 
phases of growth but by day 12 the MVSCs have recovered and the growth rate of 
the three cell lines is comparable. 
 A10 and A7r5 cells express Sca-1+ suggesting that these cells also 
display some perivascular markers. Vascular Sca-1+ is mainly attributed to 
adventitial progenitor cells but has also been identified in a side population of medial 
progenitor cells that are capable of differentiation down the SMC lineage (Hu et al. 
2004; Sainz et al. 2006; Xu 2008). The presence of c-kit and Flt-1 positive cells 
within A10 and A7r5 cells is associated with SMCs that are derived from large 
arteries of older vessels and may suggest a stem cell origin (Ferlosio et al. 2012). 
Interestingly, Hibbert et al. 2004 found that vascular progenitor cells positive for c-
kit populated human coronary in-stent restenosis but cells found in patients with 
primary atherosclerotic lesions were void of c-kit. 
The discovery that resident vascular stem cells exist in the vessel wall has 
raised questions regarding the origin of smooth muscle cells in culture. It is believed 
that these cells could be derived from MVSCs and still share some of the multipotent 
properties associated with these stem cells. With regard to this three different smooth 
muscle cell lines were screened for neural stem cell markers Sox10, Sox17 and 
astrocyte marker S100β and also for smooth muscle differentiation markers SMA, 
CNN1 and SM-MHCII. All three cell lines expressed the panel of stem cell 
associated markers while still expressing SMC differentiation markers. However, the 
cells had lost their multipotent capability to be induced to other cell types (such as 
osteocytes). It is still possible that these cells were derived from resident vascular 
stem cells.  
The commercial cell lines that were used for this work were obtained using 
two different culture methods, either by enzymatic dispersal (rat and murine) or by 
explant (bovine). The interesting discovery here is that although the culture methods 
are different all three cell lines expressed the stem cell markers associated with 
MVSCs in late passage. The murine cell line used was an immortalized one yet still 
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mimicked the phenotypic profile of MVSCs. In a similar study Tang et al 2012 
suggested that the MVSC population they isolated was initially SM-MHCII-/Sox10+ 
and became SM-MHCII+/Sox10- after up to 8 weeks in culture. Similarly, Nessy et 
al. 2010 describe how their NCSC derived MSC cell population lose Sox10 
expression after treatment with TGFβ1. In contrast, this study exhibits three different 
smooth muscle cell populations in culture that clearly show retention of stem cell 
markers Sox10 with co-expression of three differentiation markers associated with 
SMCs. The co-expression of Sox10 and SM-MHCII could indicate a proliferative 
transition between MVSCs and SMCs that display both markers (Tang et al. 2012). 
It is possible there is a period of time where the cells can express both markers, as 
they become more smooth muscle cell like, they may still retain stem cell markers 
but lose the ability to carry out functional stem cell like multipotent activity, such as 
osteogenesis. 
Nestin is associated with muscle and progenitor cells (Huang et al. 2009). 
Nestin generally is not expressed in healthy vessels but upon injury the marker can 
reappear (Vaittinen et al. 2001). Huang et al. 2009 demonstrate how Nestin can be 
expressed by SMCs when grown in serum of stimulated with Thrombin, some Nestin 
positive cells were found in rSMC cultures but the percentage was low.  
The origin of these cells displaying both SMC differentiation markers (SM-
MHCII) and stem cell associated markers (Sox10) remains an issue. The ability of 
the cells to co-express these two panels of markers is clear but the reasoning behind 
this has not yet been identified. As described previously Gomez at el. 2013 have 
identified a strategy where they confirmed the origin of early passage cultured 
SMCs. They used single cell analysis and investigated the epigenetic signature for 
the Sm-2 locus. However, these SM cell lines show expression of both MVSC and 
SMC markers in late passages. There is a need for the development of an epigenetic 
signature that can identify the origin of MVSCs, until this has been developed the 
origin of cultured SMCs cannot be validated. From these results the exact origin of 
the SMCs in culture cannot be identified and it is possible that they arise from 
differentiated SMCs, MVSCs or a combination of both. 
  The plasticity of smooth muscle cells is an on-going debate in research. It is 
unclear whether SMCs are terminally differentiated or if they can trans differentiate 
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into other cell types. Gomez et al 2013 show how SMCs in atherosclerotic lesions 
have down regulated expression of differentiation markers associated with the 
contractile SMC phenotype. It has also been shown that SMCs have the ability to 
differentiate to osteocyte and skeletal lineages (D. C. Graves & Yablonka-Reuveni 
2000)(Ciceri et al. 2012; Speer et al. 2009). Bobryshev 2005 showed that SMCs in 
atherosclerotic plaques displayed features of trans differentiation into chondrocytes. 
It was found that cells with decreased SMA expression displayed a concomitant 
expression of Sox9. Similar studies were observed in ApoE deficient mice. 
A study that further supports the theory of smooth muscle cell trans 
differentiation is that mSMCs are capable of differentiation into macrophage like 
cells after treatment with cholesterol (Rong et al. 2003). When human SMCs are 
treated with a specific combination of sex steroids they were also capable of trans 
differentiation into neural stem cells with characteristics typical to that of the MVSC 
phenotype (Bukovsky 2009). Human Aortic SMCs have been shown to be capable of 
differentiation into iPS cells using a lentiviral transduction method that contained 
refined transcription factors such as Sox2, Oct4, Nanog and other factors associated 
with stem cells (Lee et al. 2010). This group then showed that these cells were 
capable of differentiation to revert back to the SMC phenotype using a gelatin and a 
commercially available smooth muscle cell specific medium.  
Other in vivo factors can influence SMC marker expression behaviour. Often 
it is very difficult to mimic these in culture even with the great advances in cell 
culture reagents available. For example, (Brown et al. 2005) showed that 
“dedifferentiated” SMCs behave differently when they are co cultured with 
endothelial cells. EC co culture promotes an up regulation in contractile SMC 
markers, other properties such as changes in cell morphology was also noted. It is 
possible that some of the unknowns or obscure results associated with SMC in 
culture are just down to the fact that the cells are not in their natural environment and 
are not receiving the factors they require to behave as they would in vivo. 
 The trans differentiation capabilities of SMCs are clearly demonstrated by the 
above examples. It is highly possible that SMCs are capable of reverting back to 
their stem cell like state but due to the expression of stem cell like markers in SMCs 
one cannot rule out the possibility that these cells have been derived from a small 
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population of MVSCs that were present at the initial time of culture and that over 
time these cells begin to dominate in culture. Further screening of different smooth 
muscle cell lines derived from different origins would provide more insight into the 
marker expression of these cell lines. It is increasingly important to identify the 
mechanisms behind SMC plasticity to create research models that can mimic what 
processes are occur in vitro which would lead to the subsequent development and 
improvement of novel or specialised drugs that can target the specific cell type.  
 Because SMCs express a neural stem cell like phenotype in serum it was 
suspected that the expression of MVSC and SMC markers could change upon 
exposure to induction media with certain external stimulants including Notch or 
TGFβ1. This was carried out by another member of the research group and it was 
found that TGFβ1 stimulation and DAPT treatment failed to have any significant 
impact on the expression ratio of SM-MHCII and Sox10 in the cells, both remaining 
positive after induction (Kennedy et al. 2014). TGFβ1 is used to promote the 
differentiation of different types of stem cells into SMCs including embryonic stem 
cells, mesenchymal stem cells and iPS cells (Guo et al. 2013; Kurpinski et al. 2010; 
Bajpai et al. 2012b). It has also been reported to suppress Sox10 expression in neural 
crest progenitor cells (John et al. 2011). Contrarily to this, DAPT inhibits Notch 
signalling pathway which is a vital mechanism for mesenchymal to smooth muscle 
differentiation (Kurpinski et al. 2010; Tang et al. 2012; Kane et al. 2011). Sox 17 
which is another stem cell like marker expressed by the MVSC population has been 
shown to act upstream of the Notch pathway and downstream of the canonical Wnt 
system and is involved in orchestrating arterial specification, therefor may be critical 
for MVSC transition to MSC in vitro (Corada et al. 2013). Interestingly Wang et al 
2012 found that the Sox17 expression in their MVSC population disappeared after 3 
weeks in culture with 10% FBS, whereas Sox17 expression persisted in the MVSC 
population isolated here, after 3 weeks incubation in regular differentiation media. 
A10 and A7r5 embryonic cell lines retained the multipotent potential to 
differentiate into adipocytes and osteocytes. However, it was found that the SMCs 
did not retain the differentiation potential associated with MSC or MVSC cell lines 
in that they could not differentiate to osteocytes or adipocytes after induction with 
specific media. 
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6.3 NE4C as a model for Multipotent Vascular Stem Cells 
As previously described, NE4C cells are a neuroectodermal stem cell line isolated 
from the fore and midbrain vesicles of 9 day old murine embryos lacking the 
functional p53 gene. This cell line would serve as a good model for MVSC cells. 
Both cell lines are of neuroectodermal origin and display stem like characteristics 
including the expression of Sox10, sox17 and S100β as well as trilineage 
differentiation capabilities. Preliminary studies were undertaken on this cell line to 
identify certain characteristics. The cells were screened for markers associated with 
the neural crest and they were found to be Nestin and Pax6 positive. In contrast to 
this MVSCs in maintenance media displayed a Nestin+/Pax6- phenotype (Tang et al. 
2012). Despite these differences in marker expression it was thought that these cells 
could be used routinely for experiments investigating SMC differentiation as well as 
using the MVSC cell line for confirmation of results. 
One of the objectives of this work was to determine whether the NE4C cell 
line mimicked the multipotent properties and phenotypic characteristics of MVSCs. 
The NE4C cells were examined for the expression of MVSC markers Sox10, Sox17 
and S100β. The cell line was positive for all three markers, this gives a further 
indication of the similarities between these cells and MVSCs. The cells must be 
deemed multipotent in order to suffice as a model for MVSCs. Like MSC and 
MVSCs the NE4C cells were capable of differentiation into osteocytes and 
adipocytes after treatment with appropriate induction media. (Billon et al. 2007) 
have also shown that quail neural crest cells are capable of adipocyte differentiation. 
Similarly, in vitro studies have shown that Sonic hedgehog can promote the 
differentiation of neural crest cells into many different cell types including 
osteocytes (Achilleos & Trainor 2012). 
Studies have indicated that neural crest stem cells have the capability to 
differentiate into SMCs under the correct conditions. The differentiation of both 
NCSCs and SMCs is associated with activation of the TGFβ1 pathways. In a model 
using Monc-1 cells Chen & Lechleider 2004 showed that TGFβ1 could be used to 
indcue SMC marker expression and characteristics within this pluripotent neural 
crest stem cell lines. This research also suggests the involvment of SMAD2/3 
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activation for the induction of the SMC lineage. An earlier study on the same cell 
line undertaken by Shah et al. 1996 also showed that TGFβ1 is an inducer of the 
SMC lineage. More recent studies have suggested that TGFβ1 can have different 
effects on neural crest cells that arise at different axial levels. For example trunk 
neural crest cells assume a SMC fate when they are induced with TGFβ1, in 
comparison, in cranial neural crest cells this fate is suppressed by TGFβ1 induction. 
Most of the studies involving NCSCs have been carried out in culture and not animal 
models, therefore the results cannot be completely validated as there are multiple 
different environmental factors that separate in vitro from in vivo studies. However, 
there is still evidence suggesting a link between NCSC differentation to SMCs. 
DiGeorge Syndrome is the most common micro deletions syndrome in adults, 
Wurdak et al. 2005 found that inactivation of TGFβ1 leads to multiple defects that 
are reminiscent of this disease. In a more recent study, Hirota et al. 2014 showed that 
serotonin induced the differentiation of a stem cell line to Smooth Muscle – rat bone 
marrow stromal cells, interestingly they found that TGFβ1 did not mediate SMC 
differentiation. 
 One of the aims of this study was to identify the NE4C transition to SMC 
lineage following treatment of TGFβ1 and PDGF-BB (exact same as MVSC 
treatement). SMC marker expression was analysed in the same manner as MVSCs 
were. Results indicated that the cells already expressed a basal level of SMA and 
CNN1 before stimulation with differentiation media. There was a slight increase in 
CNN1 after induction. SM-MHCII was not detected pre stimulation, after the 
treatment there was a clear indication of the presence of myosin. However, there 
were no visible filaments noticed as with the MVSCs. A western blot analysis was 
also carried out and an increase was observed in both CNN1 and SM-MHCII after 
treatment, but not as significant as predicted. Because the response was not as robust 
as expected, it was investigated if the cells display the receptor for TGFβ1. This was 
done by checking if Smad2/3 was being activated. No phosphoSmad was detected in 
samples that had been treated with TGFβ1. The original data suggests that TGFβ1 
differentiated NE4C cells to SMCs with myosin expression presented, but the fact 
that the Smad2/3 pathway was not activated could mean that in this case TGFβ1 
works in dependently of the Smad2/3 pathway. The data presented provides a case 
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that NE4C cells may be capable of differentiation into SMCs but further 
experimental analysis is required before this can be concluded. 
Smad pathways in general are known as the central mediators of signals form 
receptors for TGFβ1. Smad4 is the central mediator of TGFβ1/BMP signalling, a 
study undertaken by Ko et al. 2007 suggested that Smad4 is not required for the 
migration of cranial neural crest cells but it is required for the development of the 
cardiac outflow tract. There is evidence that supports the theory that an alternative 
non-Smad pathway can participate in TGFβ1 signalling. Yue & Mulder 2000, review 
this and the study predates the discovery of Smads. Cell differentiation, cell 
proliferation, apoptosis and cell migration that are induced by TGF-β1 frequently 
uses abundant MAPK modules and alternatively non-Smad effectors, as described by 
Moustakas & Heldin 2005. Embryonic fibroblasts that were isolated from Smad4 
knockout mice still retained the capability of a number of cellular genes and 
responses that are associated with TGFβ (Sirard et al. 2000). An interesting study 
from Hagedorn et al. 2000 suggests that minor concentration gradient differences can 
have different effects on neural progenitor cell differentiation, it was found that 
lower doses of TGFβ promoted neurogenesis and a slight increase in the dose 
predominaltly induced apoptosis. Efficient NE4C differentiation to SMC could well 
be a case of optimising the concentration of TGFβ1.  
 
7.0  Conclusion 
In conclusion, these results suggest that multipotent resident vascular stem cells exist 
in the medial layer of the aorta, based on a rat model. The cells were deemed 
multipotent due to their expression of MVSC associated markers Sox10, Sox17 and 
S100β (Tang et al 2012) and by their potential to differentiate into SMCS, 
adipocytes and chondrocytes, similar to the way in which mesenchymal stem cells 
can produce these cell types. The cells were SM-MHCII negative upon isolation and 
did not begin to express this late stage marker until they were grown in 
differentiation media containing 10% FBS in DMEM or else media containing 
TGFβ1 and PDGFBB. The cells expressed SMA and CNN1 in maintenance media, a 
slight increase in CNN1 protein expression was observed after TGFβ1 treatment. 
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Currently, the origin of cells that are involved with vascular remodelling is highly 
debated (Majesky et al. 2011; van Oostrom et al. 2009; Cheung et al. 2012). It has 
been suggested that smooth muscle cells are not terminally differentiated and that 
they can de-differentiate and contribute to lesion formation (Gomez et al 2012). The 
SM-MHCII negative population has been associated with this de-differentiated cell 
phenotype for many years. More recent research has suggested that cells may be 
derived from resident stem progenitors that reside in the vasculature and that these 
cells contribute to the remodelling and lesion formation in vascular disease. Some of 
these populations identified are progenitor cells with similar characteristics to what 
was found here (Tang et al. 2012; Klein et al. 2011; Hu et al. 2004).  
 Another aim of this study was to investigate the stem cell properties of 
embryonic A10 and A7r5 cell lines and adult SMCs from three sources; bovine, rat 
and murine. The expression of neural crest and glial cell markers in A10 and A7r5 
cell lines suggests that these embryonic cell lines may be smooth muscle cells that 
are derived from an MVSC progenitor, a de-differentiated SMC or a combination of 
both. A10 and A7r5 cells express Sca1+ which suggests that these cells could also 
originate from the adventitial mesoderm. The re-evaluation of these cells lines with 
regard to MVSC markers means that these cells could be useful in determining the 
role of SMCs in disease. The cells present a phenotype that represents a 
neonatal/neo-intimal SMC population known to be derived from MVSC following 
vascular injury (Tang et al 2012). The results suggest that adult smooth muscle cell 
lines in culture are derived from an MVSC source by expression of neural stem cell 
markers. Primary dispersed smooth muscle cells in culture express low levels of 
MVSC markers in comparison with primary explanted MVSCs. In situ protein 
analysis has shown that very little MVSC marker expression exists (Kennedy et al 
2014). It is clear that the SMC lines acquire MVSC markers by de-differentiation or 
they may be outgrown by a small population of MVSC present in initial cultures. 
Further studies such as lineage tracing mechanisms would provide more insight into 
the developmental origin of these cell types. 
 The origin of smooth muscle cells in culture is also challenged by the data. 
When SMCs in the vessel are analysed they are highly positive for SM-MHCII and 
express relatively no Sox10. This data is consistent with Tang et al 2012 using in situ 
analysis of tissue sections. A small population of these cells displayed a Sox10+/SM-
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MHCII- phenotype. When this tissue was cultured and cells explanted away from the 
tissue the cells first off the explants were of the latter phenotype. When regular adult 
smooth muscle cells and embryonic smooth muscle cells were analysed in culture 
they displayed a Sox10+/SM-MHCII+ phenotype, sometimes showing a low response 
for SM-MHCII. This indicates that the cells in culture do not represent the same 
smooth muscle cell phenotype that is present in vivo. It is possible that when the 
smooth muscle cells initially were isolated that the minority MVSC population in the 
culture eventually outgrew the other SMCs. This would reason as to why we see the 
Sox10 expression in our SMC lines. Another possibility is that the vascular SMC is a 
stem cell and not fully differentiated, capable of de-differentiation into a progenitor 
cell. In vivo, it is possible that these Sox10-/SM-MHCII+ cells of the vessel wall are 
capable of differentiating into the Sox10+/SM-MHCII- cells that infiltrate into the 
lesion. The cells present in the lesion of injured vessels (Tang et al 2012) are Sox10 
positive. Smooth muscle cells in culture here present the Sox10 antigen and therefore 
represent the diseased tissue in vivo. 
Finally, neural crest stem cell line NE4C showed some potential to 
differentiate into SMCs via TGFβ treatment. Similarly to MVSCs, the cells had the 
ability to differentiate into osteocytes and adipocytes. The results suggest that the 
NE4C differentiation to SMC via TGFβ pathway works independently Smad3. 
Further experiments are required to fully conclude data for the NE4C cell line. 
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Appendices 
 
A. Antibodies 
 
 
 
Table 3.0 Antibody Cat. Number 
 
 
 
Antibody Company Cat # 
CNN (FACS) Bioss USA bs-0095R-A488 
CNN (ICC) Sigma C2687 
αActin Sigma A5228 
SM-MHCII Santa Cruz Sc79079 
SM-MHCII Abcam Ab 683 
SM-MHCII Sigma M7786 
Sox10 Abcam Ab 155279 
Sox17 Millipore 09-038 
S100β Millipore 04-1054 
CD 29 Millipore 04-1109 
CD 44 Abcam Ab 24504 
CD 146 Millipore 04-1147 
SCA 1+ Miltenyi 130-039-222 
VEGF (Flt1) Abcam Ab 32152 
SMAD3 Abcam Ab 40854 
CD 133 Biobryt orb10288 
c-kit Santa Cruz C-19 
Nestin ThermoScientific MA1-110 
Pax6 Abcam Ab 5790 
	  171	  
	  
B. Secondary antibody only controls (no primary) for 
Immunocytochemistry 
 
Figure 7 Sample images of secondary antibody only controls for 
immunocytochemistry using Alexa 488. All cell lines (A10, A7r5, rMSC, rMVSC, 
NE4C, rSMC, mSMC) were treated in the same way as regular samples but the 
samples were incubated in block buffer overnight rather than primary antibody. All 
samples were treated in the same manner from this point onwards. 
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